Clinical Trials in München, Germany, 2026

Trials with a site in München

Status

Study

Lead sponsor

Phase

Enrol

Sites in Germany

Start

Not yet open

Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)

NCT07586150Severe Mental Illness, Depression / Major Depressive Disorder, Bipolar Disorder (BD), Schizophrenia

DrugSemaglutide

Ludwig-Maximilians - University of Munich

Not applicable

140

Mannheim, München

2028-10

Not yet open

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

NCT07335562Systemic Sclerosis

DrugsZola-cel·Nintedanib·Tocilizumab·Fludarabine

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3

Berlin, Cologne, Erlangen, Leipzig, München, Tübingen, Würzburg

2027-02-03

Not yet open

A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia

NCT07084831Schizophrenia; Psychosis, Cognitive Impairment

European Group for Research In Schizophrenia

Phase 3

171

Augsburg, Cologne, Mannheim, München

2027-01-01

Recruiting

A Study to Test How Well Different Doses of BI 3822971 Are Tolerated by People With Advanced Cancer (Solid Tumours)

NCT07744152Solid Tumours

Boehringer Ingelheim

Phase 1

137

Dresden, München

2026-09-21

Recruiting

A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis

NCT07412704Arthritis, Rheumatoid

Bristol-Myers Squibb

Phase 1/2

München, Berlin, Cologne, Herne, Sendenhorst

2026-09-15

Recruiting

FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

NCT07540988Interstitial Lung Diseases

DrugNerandomilast

Boehringer Ingelheim

Phase 3

466

Berlin, Bonn, Essen, Hanover, Heidelberg, Immenhausen, München, Stuttgart

2026-09-14

Recruiting

Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide

NCT07777575Obesity (BMI>30)

Technical University of Munich

Phase 4

150

München

2026-09-07

Not yet open

A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant

NCT07613359Antibody-Mediated Rejection (AMR)

DrugMezagitamab

Takeda

Phase 2

Bochum, Essen, München, Münster

2026-09-01

Not yet open

Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma

NCT07763171Gastroesophageal Adenocarcinoma

DrugsRamucirumab·Folfox·Tislelizumab·Paclitaxel

Gruppo Oncologico del Nord-Ovest

Phase 3

244

Frankfurt, Hamburg, München, Ulm

2026-09-01

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping

NCT07587242Muscular Dystrophies, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Muscular Disorders, Atrophic, Muscular Disease

DrugAOC 1044

Avidity Biosciences, Inc.

Phase 3

Essen, Heidelberg, München

2026-09-01

Not yet open

NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

NCT07178730Breast Cancer, Triple-negative Breast Cancer

DrugsSacituzumab Govitecan·Keytruda·Pembrolizumab

Women's Cancer Study Group GmbH

Phase 3

765

Heilbronn, Weinheim, Augsburg, München, Regensburg, Würzburg, Cottbus, Bad Nauheim

2026-08-30

Not yet open

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

NCT07735637Newly Diagnosed Multiple Myeloma (NDMM)

DrugsASCT·AZD0120·Melphalan·Lenalidomide

AstraZeneca

Phase 3

750

Berlin, Dresden, Essen, Freiburg im Breisgau, Hamburg, Leipzig, München, Oldenburg

2026-08-25

Recruiting

Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease

NCT07348640Steno-occlusive Disease

DrugsGadopiclenol·Gadoterate meglumine

Guerbet

Phase 3

315

Berlin, Bonn, Essen, Homburg, Kiel, Lübeck, München

2026-07-28

Recruiting

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

NCT07492680Solid Tumors

DrugsNavlimetostat·Pumitamig·Temozolomide·Cetuximab

Bristol-Myers Squibb

Phase 2

260

Mainz, Hamburg, Heidelberg, Leipzig, München, Würzburg

2026-07-27

Recruiting

Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention

NCT07649681Multiple Myeloma (MM), GI Cancer, Taste Disorder, Melanoma (Skin Cancer)

Wuerzburg University Hospital

Not applicable

198

Augsburg, Erlangen, München, Regensburg, Würzburg

2026-07-24

Recruiting

A Study of Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter With the TRUPULSE™ Generator for Treatment of Ventricular Arrhythmias

NCT07727057Arrhythmias, Cardiac

Biosense Webster, Inc.

Not applicable

München

2026-07-08

Not yet open

AV Nodal Ablation With Conduction System Pacing Versus Cardiac Resynchronization for Symptomatic Heart Failure Patients With Atrial Fibrillation

NCT07604727Atrial Fibrillation (AF), Heart Failure, Cardiac Pacing

University Medical Center Groningen

Not applicable

292

Gelsenkirchen, Mainz, München, Paderborn, Stade

2026-07

Recruiting

KONECT RESILIA Aortic Valved Conduit (AVC) Real-world Study Assessing Safety and Performance

NCT07619872Aortic Valve Disease

Edwards Lifesciences

Observational

250

München

2026-06-25

Recruiting

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

NCT07647328ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Ribociclib

AstraZeneca

Phase 3

150

Berlin, Düsseldorf, Erlangen, Freiburg im Breisgau, Mönchengladbach, München, Paderborn, Trier

2026-06-15

Active, closed

A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

NCT07608354Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

DrugsCliramitug·Eplontersen

AstraZeneca

Phase 2

326

Berlin, Cologne, Essen, Hamburg, Heidelberg, Homburg, München, Münster

2026-06-11

Recruiting

Prospective, Non-interventional Single-arm Study With Tezepelumab to Investigate the Change in Clinical and Patient-reported Outcomes in Patients With CRSwNP in Real-world (PETRICHOR)

NCT07633158Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

AstraZeneca

Observational

200

Dortmund, Hamburg, Heilbronn, Jena, Kiel, München, Neuenhagen, Rosenheim

2026-06-10

Recruiting

An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly

NCT07583563Acromegaly

Camurus AB

Observational

200

Aachen, Leipzig, Magdeburg, München, Würzburg

2026-06-05

Recruiting

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular

Eli Lilly and Company

Phase 1

215

Berlin, München, Münster

2026-05-28

Recruiting

FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis

NCT07645443Delusional Disorder, Brief Psychotic Disorder, Schizophreniform Disorder, Schizophrenia / Schizoaffective Disorder

Stephanie Mehl

Not applicable

252

Mannheim, Augsburg, München, Hamburg, Marburg, Cologne, Berlin

2026-05-27

Recruiting

A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma

NCT07353099Thrombotic Thrombocytopenic Purpura (TTP)

Takeda

Observational

Bonn, Cologne, Jena, Leipzig, München

2026-05-26

Recruiting

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

NCT07413939HER2-positive Breast Cancer

DrugsZN-A-1041·Tucatinib·Trastuzumab·Capecitabine

Hoffmann-La Roche

Phase 2/3

650

Essen, Dessau, Hamburg, Heidelberg, Koblenz, Langen, München, Paderborn

2026-05-21

Recruiting

Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension

NCT07538388Postinduction Hypotension

Universitätsklinikum Hamburg-Eppendorf

Not applicable

446

Berlin, Düsseldorf, Hamburg, München

2026-05-07

Recruiting

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

NCT07415031Solid Tumors

DrugsAdagrasib·Leucovorin·Fluorouracil·Irinotecan

Mirati Therapeutics Inc.

Phase 2

170

München

2026-05-06

Recruiting

Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy

NCT07531927Geographic Atrophy Secondary to Age-related Macular Degeneration

Okuvision GmbH

Not applicable

Hamburg, München, Stuttgart, Tübingen, Ulm

2026-05-05

Recruiting

Glycolytic Phenotype (vLapeak) and Magnitude of Skeletal Muscle Hypertrophy After Resistance Training

NCT07721766Healthy Volunteers, Muscle Hypertrophy, Glycolysis, Moderately Trainend

Technical University of Munich

Not applicable

120

München, Cologne, Düsseldorf, Chemnitz, Leipzig

2026-05-04

Not yet open

Stratification and Treatment in Early Psychosis Study - PROMOTE

NCT07434973Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis, Clinical High Risk for Developing Psychosis

DrugCannabidiol

University of Oxford

Phase 3

586

Berlin, Cologne, Lübeck, München

2026-05-01

Recruiting

Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC

NCT07242352Breast Cancer, HR+/HER2- Breast Cancer

DrugElacestrant

Women's Cancer Study Group GmbH

Phase 3

1,520

Mannheim, Tübingen, Esslingen am Neckar, Freiburg im Breisgau, Amberg, Augsburg, München, Würzburg

2026-04-29

Recruiting

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

NCT07499232Crohn Disease

DrugsRisankizumab·Guselkumab

Janssen Research & Development, LLC

Phase 3

530

Berlin, Erlangen, Grevenbroich, Jena, Kiel, Ludwigshafen am Rhein, Mannheim, München

2026-04-21

Recruiting

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

NCT07409181Systemic Lupus Erythematosus

DrugBI 3000202

Boehringer Ingelheim

Phase 2

405

Bad Doberan, Minden, München

2026-04-20

Recruiting

Multicenter Cardiac Decision Impact Study in People With Breast Cancer

NCT07703033Breast Cancer, Cardiovascular (CV) Risk, Coronary Artery Calcifications

UMC Utrecht

Not applicable

1,000

München

2026-04-20

Recruiting

Visugromab in Cachexia International Trial

NCT07112196Cancer-associated Cachexia

DrugVisugromab

CatalYm GmbH

Phase 2/3

518

Bonn, Dresden, Großhansdorf, München

2026-04-16

Recruiting

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

NCT07227311Multiple Myeloma

DrugsVelcade·Belantamab mafodotin·Carfilzomib·Pomalidomide

GlaxoSmithKline

Phase 2

200

Frankfurt, Hamburg, Karlsruhe, Koblenz, München

2026-04-15

Recruiting

KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases

NCT06451757Mitochondrial Diseases, Maternally Inherited Diabetes and Deafness (MIDD), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS), Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation

DrugSonlicromanol

Khondrion BV

Phase 3

220

München

2026-04-14

Recruiting

A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

NCT07430306Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

245

Bad Abbach, Hamburg, Mainz, München

2026-04-13

Recruiting

DEfeating PEnile CAncer-2

NCT07378670Penile Cancer, Penile Neoplasms Malignant

University Hospital Tuebingen

Not applicable

Berlin, Dresden, Erlangen, Mainz, Mannheim, München, Rostock, Tübingen

2026-04-10

Recruiting

Clinical Performance and Safety of the Unicompartmental Univation® XF Pro Implant

NCT06657248Gonarthritis, Degenerative Disease

Aesculap AG

Observational

150

Potsdam, Bünde, Brakel, München

2026-04-02

Recruiting

Exercise Timing and Postprandial Glucose Responses

NCT07434349Exercise Timing, Postprandial Glucose

Technical University of Munich

Not applicable

München

2026-04-01

Recruiting

A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease

NCT07571746Primary Membranous Nephropathy

DrugSurovatamig

AstraZeneca

Phase 2

Düsseldorf, München

2026-03-28

Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

NCT07293351Advanced Renal Cell Carcinoma (RCC)

DrugsCasdatifan·Pumitamig·Cabozantinib·Ipilimumab

Bristol-Myers Squibb

Phase 1/2

474

Jena, Hamburg, Herne, München

2026-03-26

Recruiting

PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease

NCT07355296Proteinuric Kidney Diseases

DrugApecotrep

Boehringer Ingelheim

Phase 2

132

Berlin, Cologne, Hamburg, Hanover, Mainz, München

2026-03-23

Recruiting

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial

NCT07293260Cardiovascular Disease

DrugOlpasiran

Amgen

Phase 3

406

Berlin, Essen, Frankfurt am Main, München

2026-03-23

Recruiting

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

NCT07351045Obesity or Overweight

Hoffmann-La Roche

Phase 3

2,000

Bad Oeynhausen, Erlangen, Essen, Frankfurt, Hamburg, Hof, Köln - Dünnwald, München

2026-03-16

Recruiting

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

NCT07438496Lupus Erythematosus, Systemic

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

600

Dresden, Heidelberg, Leipzig, Meerbusch, München

2026-03-05

Recruiting

Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT)

NCT07286747Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)

University Hospital Schleswig-Holstein

Phase 2

390

Berlin, Kiel, Leipzig, Lübeck, München, Tübingen

2026-03-03

Recruiting

A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)

NCT07306559Advanced Relapsed or Refractory Germ Cell Tumours, Advanced Relapsed or Refractory Endometrial Cancer, Advanced Relapsed or Refractory Ovarian Cancer

Boehringer Ingelheim

Phase 1

187

München, Würzburg

2026-02-27

Recruiting

A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows

NCT07435428Moderate to Severe Glabellar Lines

DrugCorabotase

Ipsen

Phase 3

1,300

Darmstadt, Düsseldorf, Hamburg, Kassel, Mahlow, München, Potsdam

2026-02-18

Recruiting

Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

NCT07371585Breast Cancer Stage IV

DrugsPertuzumab·Trastuzumab deruxtecan

SOLTI Breast Cancer Research Group

Phase 2

300

München

2026-02-18

Recruiting

TRICuspid Intervention and Invasive Hemodynamic Monitoring in Heart Failure

NCT07442903Heart Failure With Severe Tricuspid Regurgitation

LMU Klinikum

Not applicable

Munich, München

2026-02-17

Recruiting

Clinical Performance and Safety Assessment of the Use of iCover Balloon Expandable Covered Stent (iVascular) Implanted as Bridging Stent in FEVAR (Fenestrated Endovascular Aortic Repair) for the Treatment of Complex Abdominal Aortic Aneurysms

NCT07529275Complex Abdominal Aortic Aneurysms

iVascular S.L.U.

Not applicable

165

Cologne, Hamburg, Leipzig, München

2026-02-16

Recruiting

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

NCT07202546HIV Infections

DrugsVH4524184·Dovato·Dolutegravir/Lamivudine

ViiV Healthcare

Phase 2

186

Berlin, Cologne, Frankfurt, Hamburg, München

2026-02-11

Recruiting

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

NCT07353931Osteoarthritis, Overweight or Obesity

DrugEloralintide

Eli Lilly and Company

Phase 3

900

Bochum, Bünde, Duisburg, Hamburg, Karlsruhe, Leipzig, München, Offenbach

2026-02-09

Recruiting

T-cell Therapy in Patients With PML

NCT06990087Progressive Multifocal Leucoencephalopathy (PML)

Hannover Medical School

Phase 2

München, Marburg, Hanover, Düsseldorf, Essen, Kiel

2026-02-06

Recruiting

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

NCT07222332Diabetes Mellitus, Type 1

DrugBaricitinib

Eli Lilly and Company

Phase 3

300

Hanover, Hof, Karlsburg, Ludwigshafen am Rhein, München, Oldenburg, Sankt Augustin, Ulm

2026-02-05

Recruiting

Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

NCT07284472Agitation Associated With Alzheimer's Disease Dementia

Exciva GmbH

Phase 2/3

300

Böblingen, Ebersberg, München, Berlin

2026-02-02

Recruiting

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

NCT07322003Amyotrophic Lateral Sclerosis

DrugPridopidine

Prilenia

Phase 3

500

Berlin, Bonn, Jena, München, Ulm

2026-02-01

Recruiting

Targeting Real World Usage In Stroke Treatment

NCT07474935Saccular and Fusiform Aneurysms, Pseudoaneurysm, Vascular Dissection, Perforation

Phenox GmbH

Observational

5,000

Erfurt, Hamburg, Heidelberg, München, Nuremberg

2026-01-29

Active, closed

A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

NCT07230860Dermatitis, Atopic

Janssen Research & Development, LLC

Phase 2

189

Berlin, Bramsche, München, Münster

2026-01-20

Recruiting

A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy

NCT06931717Non-Small Cell Lung Cancer

DrugCemiplimab

ETOP IBCSG Partners Foundation

Phase 3

390

Buch, Essen, München, Oldenburg

2026-01-12

Recruiting

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

NCT07222137Diabetes Mellitus, Type 1

DrugBaricitinib

Eli Lilly and Company

Phase 3

150

Augsburg, Dresden, Hanover, München

2026-01-12

Recruiting

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

NCT07155226Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes

DrugPosaconazole

AstraZeneca

Phase 1/2

Dresden, Frankfurt A. Main, Halle, Heidelberg, München, Ulm

2026-01-09

Recruiting

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07179380Pulmonary Hypertension, Interstitial Lung Disease

DrugTreprostinil Palmitil

Insmed Incorporated

Phase 3

344

Heidelberg, Immenhausen, Stuttgart, München, Bonn, Essen, Homburg, Dresden

2026-01-07

Recruiting

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)

DrugsPF-08634404·Pembrolizumab

Pfizer

Phase 3

1,410

München, Frankfurt am Main, Kassel, Georgsmarienhütte, Chemnitz, Halle, Lübeck, Berlin

2026-01-06

Recruiting

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

NCT07063745Metastatic Non-small Cell Lung Cancer With MTAP Deletion

DrugsNavlimetostat·Nab-paclitaxel·Pemetrexed·Paclitaxel

Bristol-Myers Squibb

Phase 2/3

590

Göppingen, Stuttgart, Tübingen, Ulm, Donauwörth, München, Regensburg, Traunstein

2026-01-02

Recruiting

The ISAR InflEx Trial (Inflammation and Exercise)

NCT07543666Inflammation, Obesity (Disorder)

Department of Cardiology German Heart Center Munich TUM University Hospital

Not applicable

München

2026-01-01

Recruiting

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT07225946Prostatic Neoplasms, Castration-Resistant

DrugsPasritamig·Prednisone/Prednisolone·Docetaxel

Janssen Research & Development, LLC

Phase 3

800

Dresden, Duisburg, Essen, Hamburg, München, Nürtingen

2025-12-19

Recruiting

Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities

NCT06722183Colorectal Cancer

DrugTislelizumab

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2

Amberg, Berlin, Düsseldorf, Essen, Frankfurt am Main, Hamburg, Mainz, München

2025-12-16

Recruiting

Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma

NCT07270991Metastatic Oesogastric Adenocarcinoma

DrugsTrifluridine/Tipiracil·Fruquintinib

Federation Francophone de Cancerologie Digestive

Phase 3

324

Chemnitz, Essen, Frankfurt, Hamburg, Jena, Leipzig, München, Rostock

2025-12-15

Recruiting

A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma

NCT07059299Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Resectable Esophagogastric Adenocarcinoma

DrugTislelizumab

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 1

Frankfurt, Hamburg, Leipzig, München

2025-12-12

Recruiting

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

NCT07222800Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site

DrugsPF-08634404·Avastin·Bevacizumab

Pfizer

Phase 3

800

Frankfurt am Main, Leipzig, Berlin, Dresden, Hamburg, München

2025-12-11

Recruiting

BaLloon-based PFA Ablation poST Approval Outcomes for PAF and PersAF

NCT07181590Paroxysmal AF, Atrial Arrhythmia, Atrial Fibrillation, Persistent Atrial Fibrillation

Abbott Medical Devices

Not applicable

300

Bad Oeynhausen, Cologne, Hamburg, München

2025-12-11

Recruiting

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody

NCT07285213Clostridioides Difficile Infection

AstraZeneca

Phase 2

230

Augsburg, Berlin, Cologne, Frankfurt, Hamburg, Jena, Leipzig, München

2025-12-10

Recruiting

Medulloblastoma Online Video-based Exercise Pilot Study

NCT06898684Medulloblastoma, Childhood

Aron Onerup

Not applicable

München

2025-12-09

Recruiting

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

NCT07226986PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

DrugsAbiraterone·Enzalutamide

Novartis Pharmaceuticals

Phase 1/2

123

Dresden, Essen, München, Stuttgart

2025-12-05

Recruiting

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)

NCT07276724Severe Asthma

DrugGB-0895

Generate Biomedicines

Phase 3

786

Deggingen, München, Frankfurt am Main, Witten, Leipzig, Lübeck, Berlin

2025-12-03

Recruiting

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

NCT07218926Gastrointestinal Neoplasms

DrugsIDRX-42·Sunitinib

GlaxoSmithKline

Phase 3

450

München, Cologne, Essen, Dresden, Berlin, Mannheim, Tübingen

2025-12-03

Recruiting

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

NCT07201558Rheumatoid Arthritis, Systemic Lupus Erythematosus

DrugSurovatamig

AstraZeneca

Phase 1

Bonn, Jena, Mainz, München, Münster

2025-12-02

Recruiting

Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment

NCT07281833Breast Cancer, HR-positive Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer

DrugCapivasertib

Women's Cancer Study Group GmbH

Phase 3

250

Cologne, Essen, Mönchengladbach, Münster, Frankfurt, Hamburg, Hildesheim, München

2025-11-27

Recruiting

Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

NCT07160608Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Alexion Pharmaceuticals, Inc.

Phase 2

Berlin, Essen, Göttingen, Ludwigshafen, München

2025-11-26

Active, closed

A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

NCT07217015Atopic Dermatitis

DrugKT-621

Kymera Therapeutics, Inc.

Phase 2

200

Augsburg, München, Bad Bentheim, Berlin, Dresden, Frankfurt, Friedrichshafen, Mainz

2025-11-24

Recruiting

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer

DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed

AstraZeneca

Phase 1/2

152

München, Münster, Oldenburg, Regensburg, Würzburg

2025-11-24

Recruiting

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

NCT07186842Advanced Solid Cancers

BioNTech SE

Phase 1/2

245

Bochum, München, Ulm

2025-11-18

Recruiting

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

NCT06804811NonSegmental Vitiligo

DrugRuxolitinib

Incyte Corporation

Phase 3

250

Berlin, Erlangen, Hamburg, Kiel, Leipzig, Mainz, München, Münster

2025-11-13

Recruiting

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration

ADARx Pharmaceuticals, Inc.

Phase 2

240

Bonn, Sulzbach, Cologne, Giessen, Mainz, München, Münster, Tübingen

2025-11-10

Recruiting

A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

NCT07088926Bronchiectasis With Pseudomonas Aeruginosa Colonization

DrugAZD0292

AstraZeneca

Phase 2

435

Berlin, Darmstadt, Essen, Frankfurt, Halle, Hanover, Konstanz, München

2025-11-06

Recruiting

Study to Collect Real-world Performance and Safety Data on Penumbra System® in Population With Acute Ischemic Stroke (AIS).

NCT07107022Acute Ischemic Stroke (AIS)

Penumbra Inc.

Observational

200

München, Recklinghausen, Augsburg, Lübeck

2025-11-01

Recruiting

Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)

NCT07123155Pompe Disease

Shionogi

Phase 2

Halle, Höchheim, München

2025-10-30

Recruiting

A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis

NCT07201051Bronchiectasis

DrugGSK3862995B

GlaxoSmithKline

Phase 2

363

Bendorf, Berlin, Frankfurt, Geesthacht, Hamburg, München

2025-10-30

Active, closed

A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

NCT07076121Pancreatic Ductal Adenocarcinoma

DrugsNavlimetostat·Abraxane·Nab-paclitaxel·Gemcitabine

Bristol-Myers Squibb

Phase 2/3

470

München, Frankfurt am Main, Göttingen, Bochum, Chemnitz, Dresden, Berlin, Cologne

2025-10-23

Recruiting

Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).

NCT06431776Autoimmune Pulmonary Alveolar Proteinosis

DrugMolgramostim

Savara Inc.

Phase 3

München

2025-10-22

Recruiting

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

NCT07177339Pulmonary Disease, Chronic Obstructive

DrugDepemokimab

GlaxoSmithKline

Phase 3

1,196

Berlin, Frankfurt, Mainz, München

2025-10-20

Active, closed

A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)

NCT07176390Arthritis, Rheumatoid

DrugsTulisokibart·Methotrexate

Merck Sharp & Dohme LLC

Phase 2

185

München, Cottbus, Ratingen, Berlin, Hamburg

2025-10-08

Recruiting

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma

DrugPonsegromab

Pfizer

Phase 2/3

982

München, Düsseldorf, Dresden, Leipzig, Berlin

2025-10-03

Recruiting

The HIgh-fidelity Hydraulic couPling Upper-arm Cuff Assessment of Limits, Safety, and Effectiveness (HIPULSE) Trial

NCT06895590Non-cardiac Surgical, Intensive Care Unit (ICU)

Philips Clinical & Medical Affairs Global

Observational

205

München

2025-10-02

Recruiting

#AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-implementation Trial.

NCT06900829HIV Infection, HIV, Stigma, Education

Casper Rokx

Not applicable

5,200

Berlin, Cologne, München

2025-10-01

Recruiting

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

NCT07197866Multiple System Atrophy

DrugEmrusolmin

Teva Branded Pharmaceutical Products R&D LLC

Phase 2

200

Dresden, Düsseldorf, Kassel, Marburg, München, Münster

2025-09-30

Not yet open

Protoporphyrin Imaging in Multispectral Evaluation of Resections

NCT07021573Glioma

Medical University Innsbruck

Not applicable

Berlin, Freiburg im Breisgau, Göttingen, München, Münster, Tübingen

2025-09-30

Recruiting

Long-Term Burden of BPD and Health-Related Quality of Life (BronQ Family)

NCT07134387Bronchopulmonary Dysplasia (BPD), Chronic Lung Disease of Newborn, HRQOL (Health Related Quality Of Life)

Global Foundation for the Care of Newborn Infants

Observational

480

München

2025-09-16

Recruiting

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

NCT07153471Osteoarthritis

DrugOrforglipron

Eli Lilly and Company

Phase 3

800

Bochum, Dresden, Hamburg, Hanover, Karlsruhe, Leipzig, München, Offenbach

2025-09-15

By invitation

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.

NCT06549400Myotonic Dystrophy

DrugMexiletine

Lupin Ltd.

Phase 3

176

München

2025-09-12

Recruiting

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

NCT06926868Breast Neoplasms

DrugsIza-bren·Nab-paclitaxel·Capecitabine·Gemcitabine

Bristol-Myers Squibb

Phase 2/3

600

Esslingen am Neckar, Augsburg, München, Frankfurt am Main, Langen, Hanover, Düsseldorf, Essen

2025-09-11

Recruiting

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

NCT06855771Carcinoma, Non-Small-Cell Lung

DrugsNavlimetostat·Iza-bren

Bristol-Myers Squibb

Phase 2

182

München, Frankfurt am Main, Halle, Cologne, Würzburg

2025-09-09

Active, closed

Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg

NCT05569239Influenza

Osivax

Phase 2

2,850

München

2025-09-08

Recruiting

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT07164443Metastatic Castration-resistant Prostatic Neoplasms

DrugsJNJ-87189401·Pasritamig

Janssen Research & Development, LLC

Phase 3

1,203

Braunschweig, Duisburg, Düsseldorf, Essen, Frankfurt am Main, Hamburg, Heidelberg, München

2025-09-02

Recruiting

Assessment of Daily Stressors in Children With Depressive Symptoms for the Development of a Gamified Emotion Regulation App

NCT07159347Depressive Disorder, Depression in Children, Depressive Symptoms

Ludwig-Maximilians - University of Munich

Observational

München

2025-09-02

Recruiting

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

NCT07070232Advanced Solid Tumor

DrugsBNT326·Paroxetine·Itraconazole·Pumitamig

BioNTech SE

Phase 1/2

1,438

Berlin, Essen, Mainz, München, Tübingen

2025-08-12

Recruiting

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

NCT07099898Neoplasms, Lung

DrugsRis-Rez·Topotecan

GlaxoSmithKline

Phase 3

420

Karlsruhe, Löwenstein, Augsburg, Chemnitz, Esslingen am Neckar, Heidelberg, Lübeck, München

2025-08-11

Recruiting

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

NCT07094516Alzheimer's Disease

DrugVHB937

Novartis Pharmaceuticals

Phase 2

407

Berlin, München

2025-08-07

Recruiting

A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism

NCT07007793Primary Hyperaldosteronism

DrugBaxdrostat

AstraZeneca

Phase 3

250

Berlin, Düsseldorf, Kaiserslautern, München, Reinfeld (Holstein), Würzburg

2025-08-07

Recruiting

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms

Eli Lilly and Company

Phase 1

421

Erlangen, Essen, München

2025-08-06

Recruiting

HOPE Against Cancer Recurrence in HCC

NCT06717919Liver Transplantation, HCC, Oncological Outcomes

Philipp Dutkowski

Phase 4

220

Essen, Hamburg-Eppendorf, Hanover, Heidelberg, Mainz, München

2025-08-01

Recruiting

A Study With CIT-013 in RA Patients

NCT06567470Rheumatoid Arthritis

DrugsCIT-013 medium·CIT-013

Citryll BV

Phase 2

Bamberg, Berlin, München, Ratingen

2025-07-29

Active, closed

Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma

NCT07120503Asthma (Diagnosis)

DrugWIN378

Windward Bio

Phase 2

136

Berlin, München, Bendorf, Lübeck, Darmstadt, Frankfurt am Main, Leipzig, Mainz

2025-07-24

Recruiting

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis

DrugsUplizna·Inebilizumab·Blinatumomab

Amgen

Phase 2

220

Cologne, Düsseldorf, Leipzig, München

2025-07-16

Recruiting

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

NCT07013474COVID-19 Infection

DrugsIbuzatrelvir·Veklury·Remdesivir

Pfizer

Phase 3

300

München, Cologne, Hamburg, Rostock, Trier, Villingen-Schwenningen, Wuppertal

2025-07-14

Recruiting

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

NCT06991114Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA

Artiva Biotherapeutics, Inc.

Phase 2

Bonn, München

2025-07-09

Recruiting

Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC

NCT07145450PDAC

Anocca AB

Phase 1/2

Berlin, Dresden, Heidelberg, Leipzig, München, Tübingen

2025-07-03

Active, closed

A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

NCT06981078Chronic Obstructive Pulmonary Disease

DrugVerekitug

Upstream Bio Inc.

Phase 2

666

Aschaffenburg, Augsburg, Bamberg, München, Cottbus, Hamburg, Darmstadt, Frankfurt am Main

2025-07-02

Recruiting

Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis

NCT06315010NSCLC, Brain Metastases, ROS1 Gene Rearrangement

DrugRepotrectinib

MedSIR

Phase 2

München

2025-06-27

By invitation

Global Open-Label Extension Study of Del-desiran for the Treatment of DM1

NCT07008469Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy, Myotonia

Avidity Biosciences, Inc.

Phase 3

199

München

2025-06-26

Recruiting

Retrospective Natural History Study of RASopathy-associated Cardiomyopathy (RAS-CM)

NCT07344480Hypertrophic Cardiomyopathy (HCM), Heart Failure, RASopathy

Deutsches Herzzentrum Muenchen

Observational

100

München

2025-06-17

Recruiting

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

NCT06943872Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsSonrotoclax·Venclexta·Obinutuzumab·Venetoclax

BeOne Medicines

Phase 3

630

Berlin, Cologne, Dresden, Jena, Kiel, Mutlangen, München, Neubrandenburg

2025-06-11

Recruiting

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

NCT06885034Gastrointestinal Neoplasms

DrugRisvutatug Rezetecan

GlaxoSmithKline

Phase 1/2

451

Bochum, Düsseldorf, Frankfurt, Lübeck, München

2025-06-11

Recruiting

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

NCT06340568Endometrial Cancer

DrugsDoxorubicin·Docetaxel·Paclitaxel

BioNTech SE

Phase 3

480

Berlin, Essen, Kassel, München, Tübingen

2025-06-10

Recruiting

REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome

NCT06914609Angelman Syndrome

DrugObudanersen

Ionis Pharmaceuticals, Inc.

Phase 3

158

München

2025-06-10

Recruiting

SLIT ABS: Study on Patients With Autoimmune Podocytopathy

NCT07516964Nephrotic Syndrome With Edema (Diagnosis), Minimal Change Nephrotic Syndrome, Focal Segmental Glomerulosclerosis (FSGS), Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy

Meyer Children's Hospital IRCCS

Not applicable

München

2025-06-10

Recruiting

A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

NCT07038200Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1

DrugDel-brax

Avidity Biosciences, Inc.

Phase 3

200

Bonn, Göttingen, München, Ulm

2025-06-10

Recruiting

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

NCT06872125Dravet Syndrome

DrugZorevunersen

Stoke Therapeutics, Inc

Phase 3

170

Berlin, Bonn, Frankfurt, Friedberg, Heidelberg, München

2025-06-04

Recruiting

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

NCT06891443Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Sensation Disorders

DrugSepofarsen

Laboratoires Thea

Phase 3

Giessen, München, Tübingen

2025-06-04

Recruiting

Assessing Declined Liver Grafts With Normothermic Machine Perfusion to Reduce Transplant Waiting Time

NCT06874296Liver Transplantation, Liver Diseases, Surgery

Charite University, Berlin, Germany

Not applicable

186

Hamburg, Aachen, Bonn, Münster, Berlin, Hanover, München, Regensburg

2025-06-02

Recruiting

Comparison of Complication Rate, Functional Outcome and Quality of Life Between Standard Therapy Versus Fast-track Therapy in Patients Following Hip Replacement Surgery

NCT07199751Coxarthrosis

Technical University of Munich

Observational

München

2025-06-01

Recruiting

A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)

NCT06568627Venous Leg Ulcer (VLU)

DrugEscharEx

MediWound Ltd

Phase 3

216

München, Chemnitz, Berlin, Bochum, Dresden, Erlangen, Kiel

2025-06-01

Recruiting

COGSCREEN II: Early Detection of Cognitive Impairment

NCT07466394Alzheimer's Disease (AD)

Robert Perneczky

Not applicable

400

München

2025-06-01

Recruiting

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

DrugOctreotide LAR

Novartis Pharmaceuticals

Phase 3

240

Erlangen, Essen, München

2025-05-30

Recruiting

Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis

NCT06978660Transthyretin Cardiac Amyloidosis

Idoven 1903 S.L.

Observational

2,200

Bonn, München

2025-05-27

Active, closed

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

NCT06993610Hidradenitis Suppurativa (HS)

Zura Bio Inc

Phase 2

225

Bad Bentheim, Bochum, Darmstadt, Dresden, Hamburg, Heidelberg, München, Münster

2025-05-16

Recruiting

Surgical vs Transcatheter Aortic Valve Replacement in YOUNG Patients

NCT06861361Symptomatic Severe Aortic Stenosis

Ceric Sàrl

Not applicable

1,180

Frankfurt, Hamburg, München, Trier

2025-05-15

Recruiting

Clinical Trial to Investigate the Safety and Efficacy of Two Dexamfetamine Sulfate Formulations in Adults With ADHD and Moderate to Severe Depression

NCT06967857Attention-Deficit/Hyperactivity Disorder (ADHD), Depression - Major Depressive Disorder

Prof. Dr. Frank Behrens

Phase 2

105

Berlin, Bonn, Frankfurt, Leipzig, München

2025-05-15

Active, closed

Study of GS-0151 in Participants With Rheumatoid Arthritis

NCT06902519Rheumatoid Arthritis

Gilead Sciences

Phase 1

Cologne, Hamburg, München

2025-05-14

Recruiting

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

NCT07003425Atopic Dermatitis

DrugAPG777

Apogee Therapeutics, Inc.

Phase 2

350

Heidelberg, Tübingen, Augsburg, München, Blankenfelde-Mahlow, Darmstadt, Frankfurt am Main, Bad Bentheim

2025-05-14

Active, closed

FARAPULSE Workflow Assessment Registry

NCT06656884Atrial Fibrillation (AF)

Boston Scientific Corporation

Observational

524

Düsseldorf, Karlsruhe, München

2025-05-06

Recruiting

VR Pupillometry in Cognitive Impairment

NCT07402356Alzheimer s Disease, Major Depressive Disorder (MDD), Mild Cognitive Impairment, Dementia

Max-Planck-Institute of Psychiatry

Observational

140

München

2025-05-01

By invitation

A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I

NCT06926621Myotonic Dystrophy Type 1 (DM1)

DrugVX-670

Vertex Pharmaceuticals Incorporated

Phase 2

München

2025-04-28

Recruiting

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

NCT06875310Carcinoma, Non-Small-Cell Lung

DrugsAdagrasib·Pemetrexed·Cisplatin·Carboplatin

Mirati Therapeutics Inc.

Phase 3

630

Esslingen am Neckar, Ulm, München, Frankfurt am Main, Giessen, Hanover, Oldenburg, Cologne

2025-04-24

Active, closed

A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's

NCT06928142Sjogren Disease

DrugSibeprenlimab

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 2

Freiburg im Breisgau, Cologne, Hamburg, München

2025-04-23

Active, closed

Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

NCT06814145Hypertension, Pulmonary

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 2

440

Heidelberg, München, Giessen, Cologne, Mainz, Dresden, Berlin

2025-04-16

Recruiting

A Contrast Medium Sparing Strategy Using Automated CO2 Injection During PVI for Prevention of Major Adverse Kidney Events (MAKE)

NCT06656988Peripheral Vascular Diseases, Kidney Diseases

University of Leipzig

Phase 3

1,960

Alsfeld, Bad Krozingen, Bonn, Chemnitz, Flensburg, Frankfurt a.M., Leipzig, München

2025-04-14

Recruiting

A Clinical Study of Arfolitixorin in Patients With mCRC

NCT06922383Metastatic Colorectal Cancer (mCRC)

Isofol Medical AB

Phase 1/2

Berlin, Essen, München

2025-04-10

Recruiting

FDG-PET/CT vs. CT for Monitoring Metastatic Breast Cancer

NCT06877949Metastatic Breast Cancer, Response Monitoring

Odense University Hospital

Not applicable

420

München

2025-04-02

Active, closed

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

NCT06764485Metastatic Castration-resistant Prostate Cancer

DrugsAbiraterone·Enzalutamide·Docetaxel

Celgene

Phase 3

960

Nürtingen, München, Lübeck, Jena, Bonn, Essen, Hamburg, Heidelberg

2025-03-13

Recruiting

A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy

NCT06854640Sepsis, Coagulopathy

DrugBAY3389934

Bayer

Phase 1

München, Cologne, Dresden, Leipzig

2025-03-12

Recruiting

177Lu-DOTATATE for Recurrent Meningioma

NCT06326190Recurrent Meningioma

DrugsLuTate·Lutathera

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2

136

Essen, Frankfurt, Heidelberg, München

2025-03-10

Recruiting

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

NCT06742996Mantle Cell Lymphoma, B Cell Lymphoma

DrugsSonrotoclax·Zanubrutinib

BeOne Medicines

Phase 3

300

Chemnitz, Frankfurt am Main, Halle, Hamburg, Mutlangen, München, Siegen

2025-03-05

Recruiting

A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)

NCT06796907Tumours, Gynecological

DrugsMo-Rez·Dostarlimab·Bevacizumab

GlaxoSmithKline

Phase 1/2

305

Cologne, Leipzig, Mainz, München

2025-03-04

Recruiting

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

NCT06671483Psoriatic Arthritis

DrugZasocitinib

Takeda

Phase 3

1,088

Bad Bentheim, Bad Doberan, Ratingen, Leipzig, Berlin, Dresden, Hamburg, München

2025-03-03

Recruiting

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer

DrugsTrastuzumab deruxtecan·Trastuzumab·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

726

Berlin, Chemnitz, Dresden, Frankfurt am Main, Hamburg, Heidelberg, Leipzig, München

2025-02-27

Recruiting

Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions

NCT07091682Coronary Artery Disease, Atherosclerosis of Coronary Artery, Myocardial Ischemia, Ischemic Heart Disease

Biotronik AG

Not applicable

100

Erfurt, Halle, Immenstadt and Kempten, München

2025-02-18

Recruiting

Low-Intensity Oscillatory Magnetic Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) - An Exposure-time Escalation Pilot Trial

NCT06533163Glioblastoma Multiforme

BioTex, Inc.

Not applicable

Stuttgart, München, Bonn, Lünen, Leipzig, Mannheim

2025-02-17

Recruiting

The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2

NCT06523400Myotonic Dystrophy

DrugMexiletine

Lupin Ltd.

Phase 3

176

München

2025-02-13

Recruiting

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

NCT06858579Chronic Inflammatory Demyelinating Polyneuropathy

DrugClaseprubart

Dianthus Therapeutics

Phase 3

256

München, Sande, Aachen, Greifswald, Rüdersdorf

2025-02-10

By invitation

A Multicenter, International, Prospective and Retrospective, Follow-up Registry to Monitor the Efficacy and Safety of the Occlutech Paravalvular Leak Device (PLD) in Patients With Mitral or Aortic Paravalvular Leaks

NCT07037446Paravalvular Leak

Occlutech International AB

Observational

200

Berlin, Dresden, München

2025-02-05

Recruiting

Long-term Evaluation of the SIMEOX Device at Home in Non-cystic Fibrosis Bronchiectasis

NCT06487273Non-cystic Fibrosis Bronchiectasis

Physio-Assist

Not applicable

622

Aachen, Lübeck, München

2025-02-03

Recruiting

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma

DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin

AstraZeneca

Phase 1/2

408

Cologne, Homburg, Kiel, Mainz, München, Würzburg

2025-01-30

Recruiting

Phase 4 Paediatric Study to Evaluate Sonazoid Safety and Efficacy for Contrast-Enhanced Ultrasound Liver Imaging

NCT06639828Focal Liver Lesions

GE Healthcare

Phase 4

München

2025-01-20

Recruiting

Lumbar Drainage of Intraventricular Hemorrhage

NCT06510842Intraventricular Hemorrhage, Lumbar Drainage, External Ventricular Drainage

University Hospital Heidelberg

Not applicable

354

Heidelberg, München, Augsburg, Berlin, Düsseldorf, Frankfurt, Göttingen, Mainz

2025-01-16

Recruiting

Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status

NCT07803848Small-cell Lung Cancer

DrugTarlatamab

AIO-Studien-gGmbH

Phase 2

Berlin, Dresden, Essen, Flensburg, Frankfurt, Minden, München, Stuttgart

2025-01-01

Recruiting

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

NCT06736574Heart Failure, Heart Failure With Reduced Ejection Fraction

Cytokinetics

Phase 3

1,800

Heidelberg, München, Würzburg, Hamburg, Erfurt, Jena, Mainz, Bad Nauheim

2024-12-19

Recruiting

The PERSEVERE Study

NCT06588634Pulmonary Embolism, Pulmonary Thromboembolism

Inari Medical

Not applicable

200

Chemnitz, Dresden, Mainz, München, Regensburg

2024-12-16

Recruiting

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT06667076Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab

Janssen Research & Development, LLC

Phase 2

480

Greifswald, Leipzig, München, Stuttgart

2024-12-16

Active, closed

Nipocalimab in Moderate to Severe Sjogren's Disease

NCT06741969Sjogrens Syndrome

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

655

Cologne, Dresden, Erlangen, Freiburg im Breisgau, Hamburg, Hanover, Herne, München

2024-12-04

Recruiting

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

NCT06472245Patients With Non-Small Cell Lung Cancer

DrugsTedopi·Docetaxel

OSE Immunotherapeutics

Phase 3

363

Heidelberg, Stuttgart, Gauting, München, Kassel, Aachen, Bonn, Essen

2024-12-03

Active, closed

A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

NCT06706622Multiple System Atrophy

DrugAmlenetug

H. Lundbeck A/S

Phase 3

401

Beelitz-Heilstätten, Erlangen, Haag in Oberbayern, München, Münster, Tübingen

2024-12-03

Recruiting

Pairing Subjective Patient Rating and DBS Programming

NCT07336199Parkinson's Disease (PD)

Ludwig-Maximilians - University of Munich

Observational

München

2024-12-02

Recruiting

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

NCT06531499Metastatic Castration-Resistant Prostate Cancer

DrugLu-PSMA

Novartis Pharmaceuticals

Phase 1

106

Cologne, Wuppertal, Aachen, Berlin, Essen, München, Rostock

2024-11-11

Recruiting

Post-market Surveillance Study to Evaluate the Quality of Life and the Safety and Effectiveness of the TIGR® Matrix After Reconstructive Breast Surgery

NCT06511167Implant Based Breast Reconstruction

AWOgyn

Observational

135

Weinheim, München, Frankfurt am Main, Wesel, Halle

2024-11-08

Recruiting

A Comparison of the Resection Rate for Hot and Cold Snare Polypectomy of Colorectal Polyps (10-15 Mm)

NCT04816292Adenomatous Polyps

Technical University of Munich

Not applicable

850

München

2024-11-05

Recruiting

EXtensive mulTilayer stEnt treatmeNt in Aortic disSectiOn

NCT06675617Type B Aortic Dissection

Intressa Vascular SA

Not applicable

Düsseldorf, Frankfurt, Kiel, Leipzig, München, Münster

2024-10-30

Active, closed

A Study of Mosliciguat in PH-ILD

NCT06635850Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases

DrugMosliciguat

Pulmovant, Inc.

Phase 2

135

Heidelberg, München, Dresden, Halle

2024-10-29

Active, closed

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06625320Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

DrugsLiposomal Irinotecan·Leucovorin·Irinotecan·Adrucil

Revolution Medicines, Inc.

Phase 3

500

Berlin, Heidelberg, München, Ulm

2024-10-16

Recruiting

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

NCT06641089Arthritis, Psoriatic

DrugsSonelokimab·Risankizumab

MoonLake Immunotherapeutics AG

Phase 3

600

Berlin, Dresden, Erlangen, Frankfurt, Hamburg, Herne, Munich, München

2024-10-15

Active, closed

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

NCT06641076Arthritis, Psoriatic

DrugSonelokimab

MoonLake Immunotherapeutics AG

Phase 3

960

Bad Bentheim, Berlin, Erlangen, Hamburg, Herne, Munich, München

2024-10-15

Recruiting

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer

Novartis Pharmaceuticals

Phase 1

162

Cologne, Essen, München, Rostock

2024-10-15

Recruiting

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

NCT06581432Solid Tumours

DrugZongertinib

Boehringer Ingelheim

Phase 2

588

Berlin, Giessen, Hamburg, Leipzig, Mannheim, München

2024-10-11

Active, closed

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

NCT06630299HIV-1-Infection

DrugsAntiretroviral Combinations·ISL/LEN

Gilead Sciences

Phase 3

600

Cologne, Hanover, Mannheim, München

2024-10-08

Recruiting

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

NCT06561386Non-small Cell Lung Cancer

DrugsRelatlimab·Pemetrexed·Nivolumab·Cisplatin

Bristol-Myers Squibb

Phase 3

1,000

Esslingen am Neckar, Ulm, Kempten (Allgäu), München, Marburg, Hanover, Dortmund, Herne

2024-10-07

Recruiting

A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

NCT06568237Multiple System Atrophy

DrugEmrusolmin

Teva Branded Pharmaceutical Products R&D LLC

Phase 2

350

Beelitz, Dresden, Düsseldorf, Kassel, Leipzig, Marburg, München, Münster

2024-10-02

Recruiting

Digital Health Promotion for Children With Congenital Heart Disease and Their Guardians

NCT06626672Congenital Heart Disease, Pediatric ALL

Deutsches Herzzentrum Muenchen

Not applicable

München

2024-10-01

Recruiting

At-Home tDCS as Maintenance Therapy

NCT07269964MDD, Severe Depression, Major Depressive Episode

Technical University of Munich

Not applicable

München

2024-10-01

Recruiting

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

NCT06492616Breast Cancer

DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole

Stemline Therapeutics, Inc.

Phase 3

4,220

Mannheim, Ulm, Augsburg, Eggenfelden, Erlangen, München, Regensburg, Rüdersdorf

2024-09-27

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

NCT06525220Head and Neck Squamous Cell Carcinoma

DrugsPetosemtamab·Pembrolizumab

Merus B.V.

Phase 3

699

Bonn, Dortmund, Dresden, Greifswald, Hamburg, Hanover, Mannheim, München

2024-09-25

Active, closed

A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

NCT06481891Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy

DrugSotagliflozin

Lexicon Pharmaceuticals

Phase 3

500

Berlin, Hamburg, Leipzig, München

2024-09-24

Recruiting

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

NCT06542250B-cell Malignancies

DrugAZD5492

AstraZeneca

Phase 1/2

174

Göttingen, München, Ulm, Würzburg

2024-09-18

Active, closed

A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

NCT06559163Systemic Lupus Erythematosus

DrugObexelimab

Zenas BioPharma (USA), LLC

Phase 2

190

München, Cologne

2024-09-17

Recruiting

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer

DrugsLeucovorin·Irinotecan·Adrucil·Cetuximab

Eli Lilly and Company

Phase 1

630

Berlin, Dresden, Essen, München

2024-09-12

By invitation

Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders

NCT06605612Inclusion Body Myositis, Myotonic Dystrophy, Limb-girdle and Facioscapulohumeral Muscular Dystrophies, Pompe Disease

LMU Klinikum

Observational

108

München

2024-09-09

Recruiting

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

NCT06274801Pulmonary Arterial Hypertension

DrugSeralutinib

Gossamer Bio USA, Inc.

Phase 3

330

Cologne, Dresden, Giessen, Heidelberg, Munich, München, Würzburg

2024-09-03

Recruiting

Liquid Biopsy Under PSMA Radioligand Therapy

NCT07118436Prostate Cancer Metastatic Castration-Resistant, Prostate Cancer

Wuerzburg University Hospital

Observational

100

Augsburg, München, Würzburg

2024-09-01

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

NCT06486441Endometrial Cancer

DrugsAdriamycin·Sacituzumab Govitecan·Taxol·Doxorubicin

Gilead Sciences

Phase 3

640

Bad Homburg, Düsseldorf, Essen, Hamburg, Hanover, Leipzig, München, Ulm

2024-08-28

Active, closed

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

NCT06413498Multiple Myeloma

DrugsAnitocabtagene Autoleucel·Carfilzomib·Pomalidomide·Bortezomib

Kite, A Gilead Company

Phase 3

452

Berlin, Cologne, Essen, Freiburg im Breisgau, Hamburg, Leipzig, München, Tübingen

2024-08-23

Recruiting

Abbott Structural Heart Device Registry

NCT06590467Heart Diseases, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect, PFO - Patent Foramen Ovale

Abbott Medical Devices

Observational

2,500

München, Bremen, Jena, Braunschweig, Berlin, Bad Rothenfelde

2024-08-21

Recruiting

Real-World NeuroModulate: Investigating Non-Invasive Brain Stimulation for Neuropsychiatric Disorders at TUM

NCT07420322Depressive Syndrom

Technical University of Munich

Observational

100

München

2024-08-15

Recruiting

One-Month DAPT in CABG Patients

NCT05997693Chronic Coronary Disease

DrugsTicagrelor·Aspirin

Weill Medical College of Cornell University

Phase 3

700

Düsseldorf, Essen, Freiburg im Breisgau, Giessen, Jena, München, Stuttgart

2024-08-15

Recruiting

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

NCT06435429Metastatic HER2-positive Breast Cancer

DrugsZanidatamab·Vinorelbine·Eribulin·Trastuzumab

Jazz Pharmaceuticals

Phase 3

550

Berlin, Dortmund, Dresden, München, Ulm

2024-08-13

Active, closed

A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

NCT06571045Diabetic Macular Edema (DME)

DrugsRestoret·Lucentis·Ranibizumab

EyeBiotech Ltd.

Phase 2/3

984

Frankfurt, Hanover, München, Münster

2024-08-07

Active, closed

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

NCT06440967Hot Flashes

DrugsFezolinetant·Tamoxifen

Astellas Pharma Global Development, Inc.

Phase 3

982

Essen, Bottrop, Dresden, Leipzig, Mönchengladbach, München, Münster, Wolfsburg

2024-07-31

By invitation

Long-term Safety and Tolerability of BHV-7000

NCT06443463Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2

660

Freiburg im Breisgau, Kehl, Ulm, Erlangen, München, Bernau bei Berlin, Marburg, Osnabrück

2024-07-30

Active, closed

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

NCT06379217Metastatic Neuroendocrine Prostate Cancer

Drugs[68Ga]Ga-PSMA-11·[177Lu]Lu-DOTA-TATE·[68Ga]Ga-DOTA-TATE·[177Lu]Lu-NeoB

Novartis Pharmaceuticals

Phase 1

München, Rostock

2024-07-29

Active, closed

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

NCT06172127HER2-positive Breast Cancer

DrugsPhesgo·Trastuzumab deruxtecan

MedSIR

Phase 2

165

Bottrop, Essen, Hamburg, München

2024-07-22

Recruiting

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

NCT06282575Biliary Tract Cancer

DrugsZanidatamab·Durvalumab·Gemcitabine·Cisplatin

Jazz Pharmaceuticals

Phase 3

286

Freiburg im Breisgau, Heidelberg, Tübingen, München, Frankfurt am Main, Hanover, Dresden, Lübeck

2024-07-19

Recruiting

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

NCT06252649Metastatic Colorectal Cancer

DrugsBevacizumab-awwb·Lumakras·Mvasi·Sotorasib

Amgen

Phase 3

450

Berlin, Chemnitz, Dresden, Essen, Frankfurt am Main, Hamburg, Ludwigsburg, München

2024-07-17

Recruiting

Observational Study of Patients With Advanced Melanoma (Skin Cancer) to Assess if IOpener®-Melanoma Test Can Predict Response to Immunotherapy.

NCT06784778Melanoma Metastatic, Melanoma, Skin, Melanoma Stage III or IV, Melanoma Advanced

Pamgene International B.V.

Observational

196

Tübingen, Heidelberg, München

2024-07-12

Recruiting

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen

DrugIvosidenib

Servier Bio-Innovation LLC

Phase 3

136

Bad Saarow, Berlin, Dresden, Hamburg, Mannheim, München, Münster, Ulm

2024-07-09

Recruiting

PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC

NCT06102057Stage III Non-small Cell Lung Cancer, Locally Advanced, Unresectable

TheraOp

Phase 2

110

Dresden, Essen, Freiburg im Breisgau, Göttingen, Homburg, Mönchengladbach, München, Oldenburg

2024-07-01

Not yet open

Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging

NCT03865277Head and Neck Squamous Cell Carcinoma

Technische Universität Dresden

Phase 2

276

Freiburg im Breisgau, Heidelberg, Mannheim, Würzburg, Dresden, Leipzig, Berlin, München

2024-07-01

Recruiting

Non Interventional German Leptomeningeal Disease Register

NCT06146010Meningeal Neoplasms, Leptomeningeal Disease

University Hospital Tuebingen

Observational

Bonn, Mannheim, München, Münster, Siegen, Tübingen, Ulm

2024-06-26

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

NCT06496178Head and Neck Squamous Cell Carcinoma

DrugPetosemtamab

Merus B.V.

Phase 3

621

Berlin, Dresden, Essen, Giessen, Greifswald, Hanover, Leipzig, München

2024-06-25

Recruiting

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

NCT06455449Polymyositis, Dermatomyositis

AstraZeneca

Phase 3

240

Bad Nauheim, Berlin, Bonn, Freiburg im Breisgau, Herne, München, Tübingen

2024-06-20

Recruiting

Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1

NCT06131983Muscular Dystrophy, Facioscapulohumeral

Sarepta Therapeutics, Inc.

Phase 1/2

München, Ulm

2024-06-19

Recruiting

Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

NCT06122584Prostate Cancer

Drug18F-PSMA-1007

ABX advanced biochemical compounds GmbH

Phase 3

380

Dresden, Düsseldorf, Gronau, Hamburg, Leipzig, München, Münster, Rostock

2024-06-13

Recruiting

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801Crohn's Disease

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,200

Pforzheim, München, Ulm, Hanover, Lüneburg, Rostock, Cologne, Duisburg

2024-06-05

Recruiting

Neuro-cardiac Rehabilitation in Youth With Congenital Heart Disease (QUALINEUROREHAB)

NCT05670132Congenital Heart Disease

University Hospital, Bordeaux

Not applicable

192

München

2024-06-03

Recruiting

Long-term Follow-up of Children Born in the PETN Studies

NCT06534307Intrauterine Growth Restriction, Pentaerithrityl Teratnitrate in Pregnancy, Long-Term Effects to Children

Jena University Hospital

Observational

228

Tübingen, Ulm, München, Hanover, Bonn, Dresden, Leipzig, Halle

2024-06-01

Active, closed

Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

NCT05739942Newly Diagnosed and Recurrent Glioblastoma

Drugs[177Lu]Lu-NeoB·[68Ga]Ga-NeoB

Novartis Pharmaceuticals

Phase 1

Essen, München

2024-05-15

Active, closed

A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)

NCT06402838Alzheimer's Disease

Hoffmann-La Roche

Phase 2

256

Berlin, München

2024-05-02

Active, closed

A Study Evaluating APG777 in Atopic Dermatitis

NCT06395948Atopic Dermatitis

DrugAPG777

Apogee Therapeutics, Inc.

Phase 2

470

Freiburg im Breisgau, Heidelberg, Tübingen, Augsburg, München, Blankenfelde-Mahlow, Darmstadt, Frankfurt am Main

2024-04-29

Recruiting

European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]

NCT06137378Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma Stage III, Laryngeal Squamous Cell Carcinoma Stage IV

DrugsKeytruda·Pembrolizumab

University of Leipzig

Phase 2

140

Mannheim, Ulm, München, Regensburg, Würzburg, Potsdam, Cologne, Leipzig

2024-04-17

Active, closed

Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer

NCT06178445Biliary Tract Cancer, HER2 Gene Mutation, HER2

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2

Augsburg, Berlin, Frankfurt, Freiburg im Breisgau, Göttingen, Hamburg, Hanover, München

2024-04-17

Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

NCT06312176Breast Neoplasms

DrugsLiposomal doxorubicin·Xeloda·Abraxane·Taxol

Merck Sharp & Dohme LLC

Phase 3

1,200

Erlangen, München, Potsdam, Georgsmarienhütte, Düsseldorf, Essen, Saarbrücken, Gera

2024-04-14

Active, closed

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

NCT06211764Non-Muscle Invasive Bladder Neoplasms

DrugsTAR-200·Mitomycin C·Gemcitabine

Janssen Research & Development, LLC

Phase 3

272

Cologne, Halle, Leverkusen, Lübeck, Mettmann, München

2024-04-09

Active, closed

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

NCT06004661Metastatic Castration-Resistant Prostate Cancer (mCRPC)

DrugsIlluccix·Lu-PSMA

Novartis Pharmaceuticals

Phase 2

Essen, München

2024-04-04

Active, closed

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

NCT06329401Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease

DrugPirfenidone

Avalyn Pharma Inc.

Phase 2

375

Munich, München, Rosenheim, Hanover, Frankfurt, Essen, Mainz, Leipzig

2024-04-03

Active, closed

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

NCT06291376Immunoglobulin A Nephropathy, IgAN

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Phase 3

579

Aachen, Berlin, Erlangen, Essen, Greifswald, Hanover, Mainz, München

2024-03-29

Active, closed

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

NCT06220201Multiple Sclerosis, Myasthenia Gravis

DrugsZola-cel·Fludarabine·Cyclophosphamide

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 1

120

Essen, Magdeburg, Düsseldorf, Erlangen, München

2024-03-28

Recruiting

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

NCT06163430Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia

Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1/2

180

Aachen, Berlin, Frankfurt am Main, Hanover, Jena, Mannheim, München

2024-03-26

Active, closed

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

NCT06333808HIV-1-infection

DrugsBictegravir·Lenacapavir·B/F/TAF

Gilead Sciences

Phase 3

577

Aachen, Berlin, Cologne, Frankfurt, Hamburg, Munich, München

2024-03-25

Recruiting

Phase 3 Clinical Trial with Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients

NCT05944016Chronic Kidney Failure in Children and Young Adults

DrugDapagliflozin

University Hospital Goettingen

Phase 3

102

Heidelberg, München, Hamburg, Frankfurt am Main, Göttingen, Cologne, Münster, Leipzig

2024-03-25

By invitation

ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation

NCT05932615Aortic Valve Stenosis, Heart Valve Diseases, Aortic Valve Disease, Heart Disease Structural Disorder

Abbott Medical Devices

Not applicable

1,500

Dortmund, Bad Nauheim, Cologne, Frankfurt, Kiel, München, Ulm

2024-03-15

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

NCT05979311HIV, HIV Infections

DrugsBictegravir·Emtricitabine·Dolutegravir·Lamivudine

ViiV Healthcare

Phase 3

307

Berlin, Cologne, Frankfurt, Hamburg, München

2024-02-21

Recruiting

Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL

NCT06134492Pneumonia, Viral, Ventilator Associated Pneumonia, Community-acquired Pneumonia, Herpes Simplex

DrugAcyclovir

Jena University Hospital

Phase 3

616

Freiburg im Breisgau, Heidelberg, Tübingen, Augsburg, München, Nuremberg, Regensburg, Rosenheim

2024-02-20

Active, closed

A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)

NCT06185764Myotonic Dystrophy Type 1 (DM1)

DrugVX-670

Vertex Pharmaceuticals Incorporated

Phase 1/2

München

2024-02-20

Active, closed

A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

NCT06260709Transthyretin Amyloid Cardiomyopathy (ATTR CM)

DrugNNC6019-0001

Novo Nordisk A/S

Phase 2

Heidelberg, München, Münster, Würzburg

2024-02-20

Recruiting

A Global Prospective Observational Registry of Patients With Pompe Disease

NCT06121011Pompe Disease

DrugsAlglucosidase alfa·Cipaglucosidase alfa·Miglustat·Avalglucosidase alfa

Amicus Therapeutics

Observational

500

Bochum, Höchheim, Marburg, München, Ulm

2024-02-16

Recruiting

Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies

NCT05966467Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD

Alexion Pharmaceuticals, Inc.

Observational

122

Dresden, Essen, München

2024-02-01

Recruiting

A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3

NCT05916313Glioma

DrugObrixtamig

Boehringer Ingelheim

Phase 1

Frankfurt, München, Tübingen

2024-01-30

Active, closed

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

NCT06208150Multiple Myeloma

DrugsElotuzumab·Talquetamab·Velcade·Teclistamab

Janssen Research & Development, LLC

Phase 3

838

Augsburg, Halle, Heidelberg, Magdeburg, München, Tübingen, Würzburg

2024-01-22

Active, closed

DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

NCT06132113Neuroendocrine Neoplasms

DrugsObrixtamig·Etoposide·Cisplatin·Carboplatin

Boehringer Ingelheim

Phase 1

München, Tübingen

2024-01-22

Recruiting

Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

NCT07159750Migraine, Episodic Migraine, Chronic Migraine, Headache

Hospital Universitari Vall d'Hebron Research Institute

Observational

700

Berlin, München

2024-01-02

Recruiting

Pacemaker Implantation Following Transcatheter Tricuspid Valve Replacement

NCT06814574AV Block Complete, Tricuspid Regurgitation (TR)

Deutsches Herzzentrum Muenchen

Observational

München

2024-01-01

Recruiting

CLL-IMPACT: A Clinical Nutrition Trial Investigating Immune and Metabolic Changes in Early-Stage CLL

NCT07487428CLL (Chronic Lymphocytic Leukemia)

Technical University of Munich

Not applicable

München

2024-01-01

Recruiting

Global Trial in APG2575 for Patients With CLL/SLL

NCT06104566CLL/SLL

DrugLisaftoclax

Ascentage Pharma Group Inc.

Phase 3

400

Dresden, München

2023-12-20

Active, closed

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

NCT05948475Cholangiocarcinoma

DrugTinengotinib

TransThera Sciences (Nanjing), Inc.

Phase 3

200

Baden, Frankfurt, Hamburg, Hanover, Heidelberg, München

2023-12-20

Recruiting

Danon Disease Natural History Study

NCT06214507Danon Disease

Rocket Pharmaceuticals Inc.

Observational

München

2023-12-20

Recruiting

Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC

NCT05718323SCLC,Extensive Stage, SLFN11-positive

DrugNiraparib

ETOP IBCSG Partners Foundation

Phase 2

München

2023-12-20

Active, closed

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

DrugZipalertinib

Taiho Oncology, Inc.

Phase 3

285

Hamburg, Giessen, München, Regensburg

2023-12-18

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

NCT06170788Non-small Cell Lung Cancer (NSCLC)

DrugsSacituzumab tirumotecan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

614

München, Nuremberg, Marburg, Hanover, Moers, Münster, Mainz, Großhansdorf

2023-12-15

Active, closed

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

NCT06007690Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma

DrugBel-sar

Aura Biosciences

Phase 3

108

Berlin, Cologne, Essen, Hamburg, Lübeck, München, Tübingen

2023-12-06

Active, closed

A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

NCT05993234HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma

DrugTrastuzumab deruxtecan

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Observational

257

Aschaffenburg, Berlin, Cologne, Essen, Göppingen, Hamburg, Hanover, München

2023-12-05

Recruiting

The Munich Cardiovascular Adaptation in Young Athletes Plus Study

NCT06259617Exercise

Technical University of Munich

Observational

250

München

2023-12-01

Recruiting

The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)

NCT06408441Epithelioid Hemangioendothelioma, Sarcoma,Soft Tissue

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Observational

100

Essen, München

2023-12-01

Recruiting

Pretreatment to Promote Graft Survival After Subsequent High-risk Corneal Transplantation [CrossCornealVision]

NCT05870566Corneal Transplantation

Claus Cursiefen

Not applicable

110

München, Cologne, Düsseldorf, Homburg, Berlin, Freiburg im Breisgau, Rostock

2023-11-20

Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

NCT05920356Non-Small Cell Lung Cancer (NSCLC)

DrugsSotorasib·Pembrolizumab

Amgen

Phase 3

750

Chemnitz, Gauting, Göttingen, Kempten, München

2023-11-16

Active, closed

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

NCT06087835Chronic Kidney Disease With High Proteinuria

DrugDapagliflozin

AstraZeneca

Phase 3

1,835

Aachen, Bad Oeynhausen, Berlin, Dresden, Hanover, Mainz, München

2023-11-07

Recruiting

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

NCT05696626Metastatic Breast Cancer

DrugsAbemaciclib·Fulvestrant

LeonaBio

Phase 3

600

Dresden, München

2023-10-31

Recruiting

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

NCT05943535Progressive Pulmonary Fibrosis, Interstitial Lung Disease

DrugTreprostinil

United Therapeutics

Phase 3

698

Rosenheim, Hanover, Bad Berka, Coswig, Essen, Immenhausen, Löwenstein, München

2023-10-30

Active, closed

Clinical and Healthcare Economic OutcoMes From ReAl-worlD Use in Europe of an AI Software During AF Ablation

NCT06083012Atrial Fibrillation, Atrial Arrhythmia, Arrhythmias, Cardiac

Volta Medical

Observational

186

München

2023-10-27

Recruiting

SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes

NCT06054035Type2diabetes, PreDiabetes, Renal Failure

DrugDapagliflozin

University Hospital Tuebingen

Phase 4

170

Berlin, Dresden, Düsseldorf, Heidelberg, Leipzig, Lübeck, München, Tübingen

2023-10-26

Active, closed

A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares

NCT06013969Generalized Pustular Psoriasis

DrugSpesolimab

LEO Pharma

Phase 4

Frankfurt am Main, München

2023-10-22

Active, closed

Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure

NCT05598333Congestive Heart Failure

AskBio Inc

Phase 2

150

München, Berlin, Freiburg im Breisgau, Hanover, Heidelberg, Kiel

2023-10-20

Active, closed

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

NCT06047444Chronic Migraine

DrugsDysport·Botulinum toxin type A

Ipsen

Phase 3

759

Berlin, Greifswald, Haag in Oberbayern, Kassel, München

2023-10-12

Active, closed

A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants

NCT06045689Myelodysplastic Syndromes

DrugsReblozyl·Luspatercept

Bristol-Myers Squibb

Phase 3

106

München, Hanover, Leipzig

2023-10-05

Active, closed

An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

NCT05900141Hyperlipoproteinemia (a)

DrugPelacarsen

Novartis Pharmaceuticals

Phase 3

Frankfurt am Main, Berlin, Cloppenburg, Dresden, Erlangen, Mainz, München, Ulm

2023-09-29

Recruiting

Prospective Evaluation of PH-impedance Tracings According to the Wingate Consensus, and Influence on GERD Classification According to the Lyon Consensus

NCT06084572GERD

Universitair Ziekenhuis Brussel

Observational

120

München

2023-09-29

Active, closed

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

NCT06047457Episodic Migraine

DrugBotulinum toxin type A

Ipsen

Phase 3

751

Berlin, Greifswald, Hessen, München

2023-09-29

Active, closed

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

NCT06088290Leiomyosarcoma

DrugsLurbinectedin·Doxorubicin

PharmaMar

Phase 3

469

München, Bad Saarow, Dresden, Hanover, Heidelberg, Manheim, Münster, Tübingen

2023-09-21

Recruiting

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

NCT05894239Metastatic Breast Cancer

DrugsPhesgo·Inavolisib

Hoffmann-La Roche

Phase 3

230

Amberg, Berlin, Bottrop, Düsseldorf, Erfurt, Erlangen, Freiburg im Breisgau, München

2023-09-08

Recruiting

Rescue of Nephrons With ALE.F02 (RENAL-F02)

NCT06047171Glomerulonephritis Rapidly Progressive

DrugsCyclophosphamid·Rituximab

Alentis Therapeutics AG

Phase 2

Berlin, Cologne, Dresden, Essen, Hanover, Leipzig, Lübeck, München

2023-09-07

Active, closed

A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

NCT05884398Metastatic Castrate-sensitive Prostate Cancer

DrugApalutamide

Janssen Research & Development, LLC

Phase 3

420

Aachen, Augsburg, Cologne, Dresden, Lübeck, München, Nürtingen, Würzburg

2023-08-31

Recruiting

A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED

NCT05966493Persistent Corneal Epithelial Defect

Glaukos Corporation

Phase 2

Mainz, München

2023-08-17

Recruiting

Study of Organ Perfusion in Heart Transplantation in Children

NCT06032195Heart Transplantation

DrugsCustodiol·Custodiol-N

Dr. F. Köhler Chemie GmbH

Phase 2

Berlin, Giessen, München

2023-08-15

Recruiting

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

NCT05803941Prostate Cancer

DrugLu-PSMA

Novartis Pharmaceuticals

Phase 4

700

Essen, München, Rostock

2023-08-14

Recruiting

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

NCT05855200Colonic Neoplasms, Neoplasms, Colon

DrugsCapeox·Dostarlimab·Folfox

GlaxoSmithKline

Phase 3

892

Berlin, Düsseldorf, Frankfurt, Halle, Lübeck, Mannheim, München

2023-08-01

Active, closed

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

NCT05933577Melanoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,089

Mannheim, Augsburg, München, Göttingen, Rostock, Cologne, Essen, Minden

2023-07-19

Active, closed

Zenith Thoracic Alpha (ZTA) Post-Market Data Collection

NCT06094127Thoracic Aortic Aneurysm, Penetrating Aortic Ulcer

Cook Research Incorporated

Observational

300

Hamburg, München, Münster

2023-07-06

Recruiting

Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML

NCT05807932Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia

DrugsMycophenolate Mofetil·Ara-C·Tacrolimus·Venetoclax

Heinrich-Heine University, Duesseldorf

Phase 1/2

Aachen, Düsseldorf, Cologne, Frankfurt, Jena, München

2023-06-26

Active, closed

Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy

NCT05583552Myelodysplastic Syndromes, Acute Myeloid Leukemia

DrugImetelstat sodium

GCP-Service International West GmbH

Phase 2

Düsseldorf, Jena, Leipzig, München

2023-06-05

Active, closed

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

NCT05881408Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc.

Phase 3

148

München, Essen, Hamburg

2023-05-31

Recruiting

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

NCT05895786Myositis

Pfizer

Phase 3

318

Ulm, Erlangen, München

2023-05-20

Active, closed

Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy

NCT05833438Acute Myeloid Leukemia (AML)

University of Leipzig

Phase 2

Berlin, Chemnitz, Cottbus, Dresden, Heidelberg, Leipzig, Mönchengladbach, München

2023-05-17

Active, closed

An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

NCT05876754Cholangiocarcinoma

DrugIvosidenib

Servier Affaires Médicales

Phase 3

299

Berlin, Dresden, Düsseldorf, Frankfurt, Freiburg im Breisgau, Hanover, München

2023-05-03

Active, closed

A Trial of Setmelanotide in Acquired Hypothalamic Obesity

NCT05774756Hypothalamic Obesity

DrugSetmelanotide

Rhythm Pharmaceuticals, Inc.

Phase 3

143

Hamburg, München, Oldenburg, Ulm

2023-04-26

By invitation

An Open-label Study of XEN1101 in Epilepsy

NCT05718817Focal Epilepsy, Tonic-Clonic Seizures

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 3

880

Aachen, Bielefeld, Frankfurt, Freiburg im Breisgau, Marburg, München, Ulm

2023-04-25

Active, closed

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

NCT05557591Advanced Non-Small Cell Lung Cancer

DrugsBNT116·Cemiplimab

Regeneron Pharmaceuticals

Phase 2

München, Frankfurt, Giessen, Halle, Kempten

2023-04-21

Active, closed

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

NCT05805501Renal Cell Carcinoma

DrugsTobemstomig·Tiragolumab·Axitinib·Keytruda

Hoffmann-La Roche

Phase 2

199

Dresden, Hamburg, Hanover, München, Nürtingen, Ulm

2023-04-21

Active, closed

A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

NCT05723562Neoplasms, Rectal

DrugDostarlimab

GlaxoSmithKline

Phase 2

154

Berlin, Dresden, Düsseldorf, Frankfurt, München

2023-04-03

Active, closed

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

NCT05705349HIV-1 Infection

DrugsDOR/ISL·B/F/TAF

Merck Sharp & Dohme LLC

Phase 3

537

München, Freiburg, Bonn, Hamburg

2023-03-08

Recruiting

Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia

NCT05366218ALL, Childhood B-Cell, Acute Lymphoid Leukemia Relapse, Acute Lymphocytic Leukemia Refractory

DrugTafasitamab

University Hospital Tuebingen

Phase 1/2

Freiburg im Breisgau, Tübingen, Ulm, München, Hamburg, Düsseldorf, Berlin, Essen

2023-03-08

Active, closed

Honeycomb: Evaluation of Radiprodil in Children with GRIN-related Disorder

NCT05818943GRIN-related Disorders

DrugRadiprodil

GRIN Therapeutics, Inc.

Phase 1

Leipzig, München

2023-03-07

Active, closed

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

NCT05649748Pulmonary Arterial Hypertension

DrugTreprostinil Palmitil

Insmed Incorporated

Phase 2/3

Heidelberg, München, Lübeck

2023-03-07

Recruiting

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

NCT05723198Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases

DrugBaricitinib

Eli Lilly and Company

Phase 3

595

Bad Bentheim, Berlin, Dresden, Frankfurt am Main, Hamburg, Mainz, München, Münster

2023-02-27

Recruiting

Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders

NCT05656469Mood Disorders, Anxiety Disorders, Psychotic Disorders

Parnassia Groep

Not applicable

2,500

Bonn, München

2023-02-23

Recruiting

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

NCT05667142Primary Generalized Tonic-Clonic Seizures

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 3

160

Aachen, Berlin, Bielefeld, Frankfurt, Freiburg im Breisgau, Marburg, München, Radeberg

2023-02-14

Recruiting

Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial

NCT05496998Mitral Regurgitation

Medtronic Cardiovascular

Not applicable

400

Bad Oeynhausen, Berlin, Bonn, Hamburg, Leipzig, Mainz, München, Ulm

2023-02-07

By invitation

A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information

NCT05718570Adult Growth Hormone Deficiency

DrugSomapacitan

Novo Nordisk A/S

Observational

400

Aachen, Frankfurt am Main, Halle, Mainz, München, Oldenburg, Würzburg

2023-02-03

Recruiting

German Validation Study of the Subjective Cognitive Decline Questionnaire (SCD-Q)

NCT06711952Alzheimer Disease, Subjective Cognitive Decline

Ludwig-Maximilians - University of Munich

Not applicable

300

München

2023-02-01

Recruiting

Clinical Value and Cost-effectiveness of a Personalized Prevention Program (PPP) in Patients With High Risk Stable CHD

NCT04433052Coronary Heart Disease

Tampere University

Not applicable

12,000

Berlin, Frankfurt, Mannheim, München, Ulm

2023-02-01

Recruiting

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

NCT05587712Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 2

Heidelberg, München, Hanover

2023-01-19

Recruiting

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

NCT05614739Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms

DrugsVepugratinib·Digoxin·Rosuvastatin·Enfortumab Vedotin

Eli Lilly and Company

Phase 1

677

München, Tübingen

2023-01-12

Active, closed

Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve

NCT05526560Mitral Stenosis, Mitral Valve Insufficiency

Edwards Lifesciences

Observational

504

Augsburg, Bad Neustadt an der Saale, Bad Oeynhausen, Bonn, Bremen, München

2023-01-11

Active, closed

A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease

NCT05662241IgG4 Related Disease

DrugObexelimab

Zenas BioPharma (USA), LLC

Phase 3

194

München, Ulm

2023-01-09

Active, closed

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

NCT05529316Advanced Melanoma

DrugsBalstilimab·Botensilimab

Agenus Inc.

Phase 2

150

Essen, Hamburg, Heidelberg, Kiel, Mainz, München, Tübingen, Würzburg

2022-12-12

Active, closed

Retention Rate of Acalabrutinib in a Non-interventional Setting

NCT05645172Chronic Lymphocytic Leukaemia (CLL)

AstraZeneca

Observational

137

D Ren, Herrsching am Ammersee, L Rrach, M Nchen, N Rnberg, Neustadt Am R Benberge, Saarbr Cken, Sindelfinden

2022-12-12

Recruiting

AIO-BNHO Comprehensive Clinico-genomics Database Network - AIO-BNHO CONNECT

NCT05701150Advanced Solid Tumor

AIO-Studien-gGmbH

Observational

3,000

Freiburg im Breisgau, Mannheim, München

2022-12-08

Active, closed

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

NCT05556096Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Phase 3

260

Berlin, Düsseldorf, München, Würzburg

2022-11-21

Active, closed

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

NCT05407324Amyotrophic Lateral Sclerosis

Corcept Therapeutics

Phase 2

279

Berlin, Bonn, Dresden, Hanover, Jena, München, Rostock, Ulm

2022-11-15

Active, closed

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

NCT05583227Eosinophilic Esophagitis

DrugTezepelumab

AstraZeneca

Phase 3

368

München

2022-11-10

Recruiting

An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe

NCT05363319Non-small Cell Lung Cancer

DrugCemiplimab

Regeneron Pharmaceuticals

Observational

500

Konstanz, Weinsberg, München, Nuremberg, Georgsmarienhütte, Rotenburg (Wümme), Münster, Troisdorf

2022-10-26

Recruiting

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

NCT05253651Colorectal Neoplasms

DrugsTucatinib·Erbitux·Herceptin·Avastin

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

400

Munich, München, Hanover, Leipzig, Amberg, Berlin, Chemnitz, Dresden

2022-10-24

Recruiting

A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

NCT05443126NSCLC

DrugPemetrexed

Ellipses Pharma

Phase 1/2

265

Berlin, Cologne, München

2022-09-30

Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT05519085Relapsed or Refractory Multiple Myeloma

DrugsMezigdomide·Velcade·Pomalidomide·Bortezomib

Celgene

Phase 3

810

München, Traunstein, Weiden, Marburg, Hanover, Bonn, Düsseldorf, Kiel

2022-09-20

Recruiting

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

NCT05243797Multiple Myeloma

DrugsTeclistamab·Lenalidomide

European Myeloma Network B.V.

Phase 3

1,594

Hamburg, Heidelberg, Jena, Lübeck, München, Nuremberg, Tübingen, Würzburg

2022-09-08

Active, closed

Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

NCT05425940Colorectal Cancer

DrugsZanzalintinib·Regorafenib·Atezolizumab

Exelixis

Phase 3

901

Hanover, Dresden, Frankfurt am Main, Hamburg, München

2022-09-07

Recruiting

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

NCT05489211Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer

DrugsPrednisone/Prednisolone·Volrustomig·Rilvegostomig·Datopotamab deruxtecan

AstraZeneca

Phase 2

454

Berlin, Essen, Hanover, München, Regensburg

2022-09-06

By invitation

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

NCT04905693Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis

DrugTreprostinil

United Therapeutics

Phase 3

1,850

Löwenstein, München, Rosenheim, Essen, Coswig, Bad Berka

2022-09-06

Active, closed

A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

NCT05399888Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia

Biogen

Phase 2

416

Mannheim, Tübingen, Ulm, Bayreuth, München, Erbach im Odenwald, Göttingen, Bonn

2022-08-24

Active, closed

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

NCT05502341HIV-1-infection

DrugsBictegravir·Lenacapavir

Gilead Sciences

Phase 2/3

689

Berlin, Bonn, Frankfurt, Hamburg, München

2022-08-16

Active, closed

A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition

NCT05061134Melanoma

DrugsCeralasertib·Durvalumab

AstraZeneca

Phase 2

194

Berlin, Buxtehude, Heidelberg, Heilbronn, Kiel, Mainz, München, Regensburg

2022-08-11

Active, closed

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

NCT05261399Carcinoma, Non-Small-Cell Lung

DrugsSavolitinib·Tagrisso·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

341

Berlin, Chemnitz, Frankfurt A. Main, Gauting, Immenhausen, Löwenstein, München, Münster

2022-08-03

Recruiting

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)

NCT04165486Multiple System Atrophy

Ionis Pharmaceuticals, Inc.

Phase 1

Ulm, Düsseldorf, Göttingen, Hanover, Marburg, München

2022-07-21

Active, closed

A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

NCT05392114Hereditary Angioedema

DrugDonidalorsen

Ionis Pharmaceuticals, Inc.

Phase 3

154

Berlin, Frankfurt, München

2022-07-13

Active, closed

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

NCT05379634Myositis

DrugNipocalimab

Janssen Research & Development, LLC

Phase 2

Berlin, München, Rüdersdorf Bei Berlin

2022-07-05

Recruiting

M-ARS ACL Post-marketing Surveillance Study

NCT04462458Anterior Cruciate Ligament (ACL) Reconstruction

Medacta International SA

Observational

200

München

2022-07-01

Recruiting

A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C

NCT05163288Niemann-Pick Disease, Type C

DrugN-Acetyl-L-Leucine

IntraBio Inc

Phase 3

Giessen, Hamburg, Höchheim, München, Münster

2022-06-30

Recruiting

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

NCT05076175Colitis, Ulcerative

DrugOzanimod

Bristol-Myers Squibb

Phase 2/3

120

München, Leipzig, Dresden

2022-05-30

Active, closed

PASS of Paediatric Patients Initiating Selumetinib

NCT05388370Neurofibromatosis Type 1

AstraZeneca

Observational

124

Dresden, Duisburg, Hamburg, Hanover, München, Tübingen

2022-05-23

Recruiting

WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC

NCT04644289Epithelial Ovarian Cancer

DrugsOlaparib·Durvalumab

AGO Research GmbH

Phase 2

Mannheim, München, Hamburg, Essen, Dresden, Berlin

2022-05-05

Active, closed

Evolut™ EXPAND TAVR II Pivotal Trial

NCT05149755Moderate Aortic Valve Stenosis

Medtronic Cardiovascular

Not applicable

650

Bad Krozingen, Bonn, Dortmund, Leipzig, Mainz, München

2022-04-27

Active, closed

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

NCT05317416Multiple Myeloma

DrugsElranatamab·Lenalidomide

Pfizer

Phase 3

854

Würzburg, Mainz, Leipzig, Kiel, Berlin, Chemnitz, Essen, München

2022-03-25

Active, closed

A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

NCT05206773Fabry Disease

DrugVenglustat

Sanofi

Phase 3

122

Hochheim am Main, Mainz, München, Würzburg

2022-03-11

Active, closed

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

NCT05132582HER2 Positive Breast Cancer

DrugsPerjeta·Tucatinib·Herceptin·Pertuzumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

654

Münster, Manheim, Mannheim, Augsburg, Berlin, Hamburg, München, Ulm

2022-03-07

Active, closed

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

NCT05215340Metastatic Non Small Cell Lung Cancer

DrugsDatopotamab deruxtecan·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

740

Berlin, Esslingen am Neckar, Großhansdorf, München

2022-03-04

Active, closed

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

NCT05120349Non-Small Cell Lung Cancer

DrugsTagrisso·Osimertinib

AstraZeneca

Phase 3

390

Berlin, Esslingen am Neckar, Georgsmarienhütte, Lübeck, München, Würzburg

2022-02-21

Active, closed

Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN

NCT05309668Neurofibromatosis Type 1

DrugSelumetinib

AstraZeneca

Phase 1/2

Hamburg, München, Tübingen

2022-01-21

Active, closed

Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study

NCT05089916NSCLC, EGFR Positive Non-small Cell Lung Cancer, Oligoprogression

DrugsTagrisso·Osimertinib

AIO-Studien-gGmbH

Phase 2

München

2022-01-20

Active, closed

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT04819100Carcinoma, Non-Small-Cell Lung

DrugSelpercatinib

Eli Lilly and Company

Phase 3

152

Heidelberg, Löwenstein, Gauting, München, Immenhausen, Georgsmarienhütte, Hanover, Münster

2021-12-20

By invitation

Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies

NCT05041309Solid and Hematological Malignancies, Autoimmune Diseases

DrugsKITE-197·SPRX002·KITE-753·Tecartus

Kite, A Gilead Company

Observational

1,500

Dresden, Hamburg, Heidelberg, Mainz, München, Würzburg

2021-12-15

Active, closed

A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

NCT05070858Generalized Myasthenia Gravis

DrugsCemdisiran·Pozelimab

Regeneron Pharmaceuticals

Phase 3

288

München, Essen, Münster, Leipzig, Berlin, Jena

2021-12-14

Recruiting

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

NCT05176483Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor

DrugsZanzalintinib·Relatlimab·Yervoy·Opdivo

Exelixis

Phase 1

1,394

Essen, Hamburg, Heidelberg, Herne, Jena, München, Nürtingen, Trier

2021-12-14

Recruiting

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

NCT04892173Carcinoma, Squamous Cell

DrugsJNJ-90301900·Erbitux·Cetuximab

Johnson & Johnson Enterprise Innovation Inc.

Phase 3

500

Giessen, Hanover, Jena, München, Rostock

2021-12-10

Recruiting

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05077904Stereotypical Prolonged Seizures

DrugStaccato alprazolam

UCB Biopharma SRL

Phase 3

350

Aachen, Berlin, Bielefeld, Erlangen, Frankfurt am Main, Kehl-kork, Marburg, München

2021-12-07

Recruiting

A Comparison of Two Psychotherapy Programs in Persistently Depressed Treatment-Resistant Inpatients

NCT04996433Persistent Depressive Disorder, Treatment-resistant Depression

University of Greifswald

Not applicable

396

Berlin, Bonn, Hanover, Jena, Lübeck, Marburg, München, Tübingen

2021-12-01

Active, closed

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

NCT04988295Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin

Janssen Research & Development, LLC

Phase 3

776

Berlin, Hamburg, Heidelberg, Heilbronn, Leipzig, Moers, München, Recklinghausen

2021-11-17

Recruiting

High Dose Steroids in Children With Stroke

NCT04873583Paediatric Stroke

DrugsSolu-Medrol·Prednisolone·Methylprednisolone

Insel Gruppe AG, University Hospital Bern

Phase 3

Freiburg im Breisgau, München, Düsseldorf, Münster, Berlin, Hanover

2021-11-16

Active, closed

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

NCT04994717Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

DrugBlinatumomab

Amgen

Phase 3

303

Augsburg, Berlin, Dresden, Düsseldorf, Heidelberg, Jena, Kiel, München

2021-11-02

Active, closed

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

NCT05043090Papillary Renal Cell Carcinoma

DrugsSavolitinib·Sunitinib·Durvalumab

AstraZeneca

Phase 3

148

Hamburg, Hanover, München, Ulm

2021-10-28

Active, closed

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

NCT05048797Locally Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsTrastuzumab deruxtecan·Pemetrexed·Cisplatin·Carboplatin

AstraZeneca

Phase 3

454

Cologne, Dresden, Mainz, München, Oldenburg

2021-10-28

Active, closed

A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

NCT07280377Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic, Unresectable Pancreatic Carcinoma

DrugsGemcitabine and nab-paclitaxel·Pelareorep·Lonsurf·Trifluridine/Tipiracil

Oncolytics Biotech

Phase 1/2

122

Heidelberg, Heilbronn, Tübingen, Ulm, Augsburg, München, Hamburg, Frankfurt am Main

2021-10-27

Active, closed

Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.

NCT05181592Myelodysplastic Syndromes

DrugsReblozyl·Luspatercept

GWT-TUD GmbH

Phase 3

Leipzig, München

2021-10-27

Recruiting

tTF-NGR Randomized Study - STS

NCT05597917Soft Tissue Sarcoma

DrugTrabectedin

Universität Münster

Phase 3

126

Bad Saarow, Berlin, Dresden, Hanover, Heidelberg, Mainz, München, Münich

2021-10-26

Recruiting

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

NCT04929223Metastatic Colorectal Cancer

DrugsDivarasib·Tiragolumab·Inavolisib·Folfiri

Hoffmann-La Roche

Phase 1

542

Berlin, Bochum, Dresden, Düsseldorf, Hamburg, Heilbronn, München, Ulm

2021-10-22

Active, closed

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

NCT05104866Breast Cancer

DrugsVinorelbine·Eribulin·Datopotamab deruxtecan·Capecitabine

AstraZeneca

Phase 3

732

Heidelberg, Homburg, Leipzig, München, Ravensburg

2021-10-18

Recruiting

ACCESS Registry: A Post Market Follow-up Study to Monitor the Safety, Performance and Usability of Occlutech Accessory Medical Devices

NCT05174442Heart Diseases

Occlutech International AB

Observational

685

Erlangen, Mönchengladbach, München

2021-10-14

Recruiting

Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)

NCT05112549Leptomeningeal Disease

DrugsOpdivo·Nivolumab

University Hospital Tuebingen

Phase 1

Bonn, Freiburg im Breisgau, Heidelberg, Heilbronn, Mannheim, München, Stuttgart, Tübingen

2021-10-12

Active, closed

Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia

NCT05011123Yellow Fever

DrugYellow fever vaccine

Sanofi Pasteur, a Sanofi Company

Phase 2

690

Berlin, Hamburg, München, Rostock

2021-10-07

Active, closed

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

NCT04975308Breast Neoplasms, Neoplasm Metastasis

DrugsImlunestrant·Exemestane·Abemaciclib·Fulvestrant

Eli Lilly and Company

Phase 3

874

Ludwigsburg, Donauwörth, Erlangen, München, Frankfurt am Main, Hanover, Essen, Mönchengladbach

2021-10-04

Recruiting

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

NCT05020236Multiple Myeloma

DrugsDarzalex·Elranatamab·Pomalidomide·Daratumumab

Pfizer

Phase 3

893

Ulm, Würzburg, Berlin, Braunschweig, Chemnitz, München

2021-10-04

Active, closed

Plasma On Chronic Wounds for Epidermal Regeneration

NCT05855499Chronic Ulcer of Lower Extremity

Coldplasmatech

Not applicable

120

Tübingen, München, Regensburg, Hamburg, Bochum, Dresden, Berlin, Saalfeld

2021-10-01

Recruiting

International Rare And Severe Psoriasis Expert Network

NCT04359394Pustular Psoriasis (PP)

University Hospital, Basel, Switzerland

Observational

180

München

2021-09-22

Recruiting

Bone Substitutes Outcomes - Post Market Follow-up

NCT06374342Bone Resorption

Teknimed

Observational

425

München

2021-09-16

Recruiting

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma

DrugTacabrutideg

BeOne Medicines

Phase 1/2

645

Cologne, Dresden, Leipzig, Lübeck, Mainz, München, Ulm

2021-09-13

Active, closed

A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

NCT04765059Non-small Cell Lung Cancer

DrugCarboplatin

AstraZeneca

Phase 3

Berlin, Cologne, Hanover, München

2021-09-12

Active, closed

RanDOmized stUdy Comparing Both Latest Generation Self-Expanding Valves and a Minimalist approaCH vs. Standard Of Care In transCathEter Aortic Valve Implantation

NCT05036018Aortic Valve Stenosis

Leipzig Heart Science gGmbH

Not applicable

836

Bad Berka, Bad Oeynhausen, Cologne, Dortmund, Giessen, Leipzig, München, Tübingen

2021-08-30

Active, closed

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

NCT04923893Multiple Myeloma

DrugsCilta-cel·Bortezomib·Lenalidomide·Fludarabine

Janssen Research & Development, LLC

Phase 3

743

Berlin, Dresden, Freiburg im Breisgau, Hamburg, Heidelberg, Leipzig, Mainz, München

2021-08-19

Active, closed

STOP Persistent AF PAS

NCT05005949Persistent Atrial Fibrillation

Medtronic Cardiac Ablation Solutions

Observational

400

Cologne, Frankfurt am Main, München

2021-08-19

Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

NCT04924075Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor

DrugBelzutifan

Merck Sharp & Dohme LLC

Phase 2

355

Freiburg im Breisgau, München, Würzburg, Düsseldorf, Berlin

2021-08-12

Active, closed

A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis

NCT05704361Multiple Sclerosis

Hoffmann-La Roche

Phase 1

119

Dresden, Göttingen, München, Münster, Tübingen, Ulm

2021-08-11

Active, closed

A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

NCT04657289Neovascular Age-related Macular Degeneration (nAMD)

DrugRanibizumab

Hoffmann-La Roche

Phase 3

451

Bonn, Cologne, Cottbus, Freiburg im Breisgau, Hamburg, Ludwigshafen, München, Münster

2021-07-14

Active, closed

Evaluation of TAVR Using the NAVITOR Valve in a Global Investigation

NCT04788888Symptomatic Severe Aortic Stenosis

Abbott Medical Devices

Not applicable

434

Bad Nauheim, Berlin, Dortmund, Dresden, Frankfurt, Hamburg, Leipzig, München

2021-07-13

Active, closed

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

NCT04915755Neoplasms, Breast

DrugNiraparib

GlaxoSmithKline

Phase 3

Berlin, Cologne, Erlangen, Essen, Mannheim, München, Ulm

2021-06-28

Active, closed

177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

NCT04689828Prostatic Neoplasms

DrugsARDT·Illuccix·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

469

Essen, München

2021-06-15

Active, closed

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT04720157Prostatic Neoplasms

DrugsARDT·Illuccix·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

1,140

Würzburg, Cologne, Essen, München, Münster, Rostock

2021-06-09

Active, closed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis

NCT04679870Myelofibrosis

Galecto Biotech AB

Phase 2

Düsseldorf, Heidelberg, Leipzig, München

2021-06-09

Recruiting

Amyloid-β Clearance Mechanisms in Alzheimer's Disease

NCT05059158Alzheimer's Disease (AD)

Ludwig-Maximilians - University of Munich

Observational

München

2021-06-01

Recruiting

ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES

NCT04503395Aortic Aneurysm, Abdominal

FCRE (Foundation for Cardiovascular Research and Education)

Not applicable

204

Aachen, Leipzig, München, Münster

2021-05-21

Recruiting

RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures

NCT04796350Fragility Fracture, Hip Fractures, Osteoporosis

AgNovos Healthcare, LLC

Not applicable

2,400

Berlin, Düsseldorf, Giessen, Hanover, Kiel, München, Münster, Regensburg

2021-04-24

Recruiting

Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).

NCT04663750Eye Diseases, Macular Degeneration, Wet, Sub-Macular Hemorrhage

King's College Hospital NHS Trust

Phase 3

210

Bonn, Hamburg, Ludwigshafen, München, Münster, Sulzbach, Ulm, Würzburg

2021-04-16

Active, closed

TRISCEND II Pivotal Trial

NCT04482062Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases

Edwards Lifesciences

Not applicable

864

Bad Oeynhausen, Bonn, Cologne, Dresden, Leipzig, Mainz, München

2021-04-09

Active, closed

SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial

NCT04722250Symptomatic Aortic Stenosis, Aortic Valve Stenosis, Aortic Valve Replacement

Medtronic Cardiovascular

Not applicable

1,103

Bad Oeynhausen, Berlin, Dortmund, Düsseldorf, Kiel, Leipzig, Lübeck, München

2021-04-02

Active, closed

Study of Dupilumab to Demonstrate Efficacy in Subjects With Nummular Eczema

NCT04600362Nummular Eczema

DrugDupilumab

Technical University of Munich

Phase 2

München

2021-03-30

Recruiting

Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature

NCT04674969Peripheral Vascular Diseases

Boston Scientific Corporation

Observational

5,000

Bruchsal, Essen, München

2021-03-29

Recruiting

Post Market Clinical Follow up Study With the Cervical Disc Prothesis MOVE®-C

NCT05035693Discopathy, Herniated Cervical Disc, Stenoses, Spinal, Radiculopathy

NGMedical GmbH

Not applicable

170

Berlin, Gelnhausen, Itzehoe, Koblenz, München, Würselen

2021-03-11

Active, closed

Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A

NCT04644575Hemophilia A

DrugEfanesoctocog alfa

Bioverativ, a Sanofi company

Phase 3

261

Berlin, Bonn, Frankfurt am Main, München

2021-02-23

Active, closed

Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

NCT04732871Respiratory Syncytial Virus Infections

GlaxoSmithKline

Phase 3

1,720

Essen, Goch, Hamburg, Mainz, München, Wallerfing, Würzburg

2021-02-15

Active, closed

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

NCT04711252ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Palbociclib

AstraZeneca

Phase 3

1,370

Berlin, Dessau-RoBlau, Essen, Freiburg im Breisgau, Mönchengladbach, München, Münster, Regensburg

2021-01-28

Active, closed

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

NCT04657991Melanoma

DrugsBinimetinib·Encorafenib·Keytruda·Pembrolizumab

Pfizer

Phase 3

257

Tübingen, München, Bonn, Minden, Mainz, Dresden, Leipzig, Kiel

2021-01-15

Active, closed

Transcatheter Repair of Tricuspid Regurgitation With Edwards PASCAL Transcatheter Valve Repair System

NCT04614402Tricuspid Valve Insufficiency

Edwards Lifesciences

Observational

300

Tübingen, Ulm, München, Cologne, Essen, Bad Oeynhausen, Bonn, Leipzig

2021-01-15

Active, closed

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

NCT04534205Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer

DrugPembrolizumab

BioNTech SE

Phase 2/3

358

Berlin, Cologne, Hanover, Heidelberg, Iserlohn, Leipzig, Mainz, München

2021-01-07

Active, closed

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

NCT04538742Metastatic Breast Cancer

DrugsTucatinib·Pertuzumab·Trastuzumab deruxtecan·Durvalumab

AstraZeneca

Phase 1/2

245

München, Würzburg

2020-12-28

Active, closed

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

NCT04522544Hepatocellular Carcinoma Non-resectable, HCC

DrugsTremelimumab·Durvalumab

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2

Bonn, Cologne, Essen, Göttingen, Hanover, Jena, Lübeck, München

2020-12-15

Active, closed

A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease

NCT04540497IgG4 Related Disease

DrugInebilizumab

Amgen

Phase 3

135

Berlin, Lübeck, München

2020-12-04

Active, closed

Non-ischemic Preservation of the Donor Heart in Heart Transplantation

NCT03991923Heart Transplantation

XVIVO Perfusion

Not applicable

230

München, Berlin, Bad Oeynhausen, Düsseldorf, Hanover

2020-11-25

Active, closed

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

NCT04557059Prostatic Neoplasms

DrugsLhrha·Apalutamide

Janssen Pharmaceutica N.V., Belgium

Phase 3

691

Berlin, Braunschweig, Dresden, Essen, München, Münster

2020-11-12

Active, closed

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

NCT04544449Multiple Sclerosis, Primary Progressive

DrugsFenebrutinib·Ocrelizumab

Hoffmann-La Roche

Phase 3

985

Berlin, Böblingen, Dresden, Freiburg im Breisgau, München, Tübingen, Wiesbaden

2020-10-26

Active, closed

Dual-sided Hypoglossal neRvE stimulAtion for the treatMent of Obstructive Sleep Apnea (DREAM)

NCT03868618Obstructive Sleep Apnea

Nyxoah S.A.

Not applicable

115

München

2020-10-14

Active, closed

A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)

NCT04093349Pompe Disease, Pompe Disease (Late-onset), Glycogen Storage Disease Type 2, Glycogen Storage Disease Type II

Spark Therapeutics, Inc.

Phase 1/2

München

2020-10-01

Recruiting

Evaluation Of Outcomes Following Rotator Cuff Repair Using the REGENETEN Bioinductive Implant

NCT06857084Rotator Cuff Injuries

Smith & Nephew, Inc.

Observational

400

Lorsch, Düsseldorf, Erlangen, Heidelberg, Herne, München, Stadtallendorf

2020-10-01

Active, closed

Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)

NCT04483739Multiple Myeloma

European Myeloma Network B.V.

Phase 3

302

Freiburg im Breisgau, Hamburg, München

2020-09-25

Active, closed

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

NCT04497844Prostatic Neoplasms

DrugsAbiraterone acetate·Prednisone

Janssen Research & Development, LLC

Phase 3

696

Braunschweig, Cologne, Dresden, Duisburg, Hanover, München, Münster, Nürtingen

2020-09-23

Active, closed

AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC

NCT04413201Non-squamous NSCLC

DrugsAfatinib·Osimertinib

Michael Hopp

Phase 4

München, Giessen, Offenbach, Berlin, Bremen, Hamburg, Hamm, Immenstadt im Allgäu

2020-09-11

Active, closed

Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)

NCT01817192Non-Small Cell Lung Cancer

Razor Genomics

Not applicable

420

Cologne, Gauting, Georgsmarienhütte, Großhansdorf, Hanover, Lübeck, München, Oldenburg

2020-09-11

Recruiting

Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)

NCT04385290Acute Myeloid Leukemia

DrugsMidostaurin·Daunorubicin

Technische Universität Dresden

Phase 1/2

214

München, Essen, Aachen, Augsburg, Chemnitz, Dresden, Frankfurt am Main, Halle

2020-09-04

Recruiting

BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment

NCT04673955Metastatic Colorectal Carcinoma

DrugsEncorafenib·Erbitux·Cetuximab

Pierre Fabre Pharma GmbH

Observational

500

Offenburg, Ulm, Augsburg, Donauwörth, Erlangen, München, Würzburg, Aschaffenburg

2020-09-03

Active, closed

Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma

NCT04733183Soft Tissue Sarcoma

DrugsOnfekafusp alfa·Dacarbazine

Philogen S.p.A.

Phase 2

Münster, Bad Saarow, Berlin, München

2020-08-28

Active, closed

Combination of Ranibizumab and Targeted Laser Photocoagulation

NCT04444492Central Retinal Vein Occlusion With Macular Edema

DrugsLucentis·Ranibizumab

University of Giessen

Phase 3

Freiburg im Breisgau, Giessen, Hanover, Leipzig, Ludwigshafen, Marburg, München, Münster

2020-08-25

Recruiting

Digital Dementia Registry Bavaria (digiDEM Bayern): a Multicentre, Prospective, Longitudinal Register Study Including People With Mild Cognitive Impairment and Dementia as Well as Their Family Caregivers

NCT07721701Mild Cognitive Disorder, Alzheimer Disease, Vascular Dementia, Dementia in Other Diseases Classified Elsewhere

University of Erlangen-Nürnberg Medical School

Observational

5,000

Aschaffenburg, Bad Aibling, Bad Neustadt an der Saale, Bayreuth, Coburg, Freyung, München, Neumarkt

2020-08-10

Active, closed

MINIject Global Long-Term Follow-up Study

NCT04524416Open Angle Glaucoma, Ocular Hypertension

iSTAR Medical

Observational

116

Cologne, Mainz, München

2020-08-05

Active, closed

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

NCT04494425Advanced or Metastatic Breast Cancer

DrugsTrastuzumab deruxtecan·Nab-paclitaxel·Capecitabine·Paclitaxel

AstraZeneca

Phase 3

866

Berlin, Dresden, Freiburg im Breisgau, Hanover, München, Münster, Velbert

2020-07-24

Active, closed

MitraClip REPAIR MR Study

NCT04198870Mitral Valve Regurgitation

Abbott Medical Devices

Not applicable

500

Ulm, Frankfurt am Main, Bad Oeynhausen, Mainz, München, Rostock

2020-07-21

Active, closed

Intensive Rhythm Monitoring to Decrease Ischemic Stroke and Systemic Embolism - the Find-AF 2 Study

NCT04371055Ischemic Stroke, Atrial Fibrillation

University of Leipzig

Not applicable

5,227

München, Nuremberg, Bremen, Leipzig, Berlin, Altenburg, Aschaffenburg, Augsburg

2020-07-07

Active, closed

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

NCT04273945Pulmonary Arterial Hypertension

DrugMacitentan

Actelion

Phase 3

935

Bad Oeynhausen, Hanover, München, Regensburg

2020-06-30

Recruiting

Characterizing the Retinal Microvasculature in Patients with Fabry Disease: a Prospective Observational Study

NCT06758648Fabry Disease, Endothelial Dysfunction, Microvasculature

Technical University of Munich

Observational

München

2020-06-25

Active, closed

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

NCT04224493Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma

DrugTazemetostat

Epizyme, Inc.

Phase 3

599

Schwäbisch Hall, München, Mainz, Bonn, Mönchengladbach, Kiel, Berlin

2020-06-11

Active, closed

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

NCT04379596Gastric Cancer

DrugsVolrustomig·Rilvegostomig·Trastuzumab deruxtecan·Fluorouracil

AstraZeneca

Phase 2

452

Frankfurt, Hamburg, Leipzig, Mannheim, München

2020-06-03

Active, closed

Adipositas Care & Health Therapy

NCT04768127Patients After Metabolic-bariatric Surgery, Obesity, Morbid

Wuerzburg University Hospital

Not applicable

586

Gräfelfing, Memmingen, München, Nuremberg, Offenbach, Passau, Würzburg

2020-05-15

Recruiting

Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis

NCT03993262Autoimmune Encephalitis

DrugBortezomib

Jena University Hospital

Phase 2

München, Würzburg, Jena, Hanover, Berlin, Bochum, Düsseldorf, Erlangen

2020-05-13

Recruiting

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT04221542Prostate Cancer

DrugsXaluritamig·Abiraterone·Enzalutamide

Amgen

Phase 1

479

Essen, Heidelberg, München, Münster

2020-03-04

Active, closed

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

NCT04211337Medullary Thyroid Cancer

DrugsVandetanib·Selpercatinib·Cabozantinib

Loxo Oncology, Inc.

Phase 3

291

München, Würzburg, Hanover, Essen, Mainz, Magdeburg, Berlin, Hamburg

2020-02-11

Active, closed

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

NCT04175600Hypertension, Pulmonary

DrugSelexipag

Actelion

Phase 3

138

Freiburg im Breisgau, Heidelberg, Leipzig, München

2020-01-16

Active, closed

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

NCT04129502Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

DrugsMobocertinib·Pemetrexed·Cisplatin·Carboplatin

Takeda

Phase 3

354

Heidelberg, München, Regensburg, Frankfurt am Main, Oldenburg, Berlin

2020-01-10

Active, closed

Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia

NCT04150887Leukemia, Myeloid, Acute

DrugsCusatuzumab·Venclexta·Azacitidine·Venetoclax

OncoVerity, Inc.

Phase 1

Hamburg, Leipzig, München

2019-12-23

Recruiting

Medtronic Cardiac Surgery PMCF Registry

NCT04073420Valve Disease, Heart

Medtronic Cardiac Surgery

Observational

2,700

Bad Rothenfelde, Dresden, Düsseldorf, Hamburg, Leipzig, München

2019-12-02

Active, closed

Safety and Efficacy of Silk Vista and Silk Vista Baby Flow Diverter for Intracranial Aneurysm Treatment

NCT04034810Intracranial Aneurysm, Flow Diverter

Balt Extrusion

Observational

234

München

2019-11-04

Active, closed

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

NCT04099251Melanoma

DrugsOpdivo·Nivolumab

Bristol-Myers Squibb

Phase 3

790

München, Bonn, Buxtehude, Dresden, Essen, Gera, Göttingen, Hanover

2019-10-28

Active, closed

SJM Masters HP 15mm Rotatable Mechanical Heart Valve as Aortic Valve Replacement Therapy

NCT03924661Aortic Valve Disease

Abbott Medical Devices

Observational

Stuttgart, München, Leipzig, Hanover

2019-10-24

Recruiting

Phenotypes, Biomarkers and Pathophysiology in Hereditary Spastic Paraplegias and Related Disorders

NCT03981276Hereditary Spastic Paraplegia

Dr. Rebecca Schule

Observational

2,000

Bonn, Erlangen, Essen, Göttingen, Heidelberg, Lübeck, Magdeburg, München

2019-10-14

Active, closed

Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer

NCT04050436Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma

DrugsVusolimogene Oderparepvec·Cemiplimab

Replimune, Inc.

Phase 2

231

Berlin, Essen, Hamburg, Heidelberg, München, Tübingen

2019-10-08

Active, closed

PULSTA Transcatheter Pulmonary Valve Pre-Approval Study

NCT03983512Heart Diseases, Pulmonary Valve Regurgitation, Pulmonary Valve Stenosis, Tetralogy of Fallot

Taewoong Medical Co., Ltd.

Not applicable

München

2019-10-07

Active, closed

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

NCT03975647HER2-positive Breast Cancer

DrugsTucatinib·Trastuzumab emtansine

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

466

Mainz, Kiel, Koblenz, München, Offenbach/ Main

2019-10-02

Active, closed

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

NCT03989414Multiple Myeloma

DrugsElotuzumab·Mezigdomide·Isatuximab·Carfilzomib

Celgene

Phase 1/2

424

Freiburg im Breisgau, Hamburg, Heidelberg, München, Würzburg

2019-09-30

Active, closed

Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia

NCT03620903Waldenstrom Macroglobulinemia

Christian Buske

Phase 2

Bielefeld, Bremen, Halle, Mannheim, Mönchengladbach, Mutlangen, München, Münster

2019-09-11

Active, closed

A Post-market Clinical Follow up of the Genio® System for the Treatment of Obstructive Sleep Apnea in Adults

NCT04031040Obstructive Sleep Apnea

Nyxoah S.A.

Not applicable

110

Hamburg, Jena, Mannheim, München, Wuppertal

2019-09-01

Active, closed

MiCLASP Post Market Clinical Follow-Up (PMCF) Study

NCT04430075Mitral Regurgitation, Mitral Insufficiency

Edwards Lifesciences

Observational

1,000

Bad Krozingen, Tübingen, Ulm, Erlangen, München, Bernau bei Berlin, Giessen, Göttingen

2019-08-23

Active, closed

TRILUMINATE Pivotal Trial

NCT03904147Tricuspid Regurgitation

Abbott Medical Devices

Not applicable

572

München, Bonn, Mainz, Leipzig

2019-08-21

Active, closed

Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia

NCT04119050Warm Autoimmune Hemolytic Anemia

DrugNipocalimab

Janssen Research & Development, LLC

Phase 2/3

118

Berlin, Essen, München

2019-08-15

Active, closed

Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma

NCT03937843Seminoma, Testicular Cancer

DrugsEtoposide·Cisplatin·Carboplatin

Swiss Cancer Institute

Phase 2

135

München, Berlin, Essen, Hamburg, Ludwigsburg, Tübingen, Ulm

2019-07-29

Active, closed

IMPEDE and IMPEDE-FX Embolization Plug Registry

NCT04044443Peripheral Vascular Embolization

Shape Memory Medical, Inc.

Observational

108

Dresden, Heidelberg, Kiel, Leipzig, München, Nuremberg, Stuttgart, Würzburg

2019-07-09

Active, closed

accuRate Evaluation of Benefit With Optimal Medical Treatment With or Without Transcatheter Valve Repair of PARADOXical Low Flow Low Gradient Aortic Stenosis

NCT03863132Aortic Valve Stenosis

IHF GmbH - Institut für Herzinfarktforschung

Not applicable

120

München

2019-07-03

Recruiting

E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe

NCT03818503Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Observational

2,000

Aachen, Bayreuth, Dresden, Mönchengladbach, München

2019-06-24

Active, closed

Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study

NCT03886246Generalized Pustular Psoriasis

DrugSpesolimab

LEO Pharma

Phase 2

131

Bad Bentheim, Berlin, Bonn, Erlangen, Frankfurt am Main, München, Münster, Oldenburg

2019-05-29

Active, closed

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

NCT03887455Early Alzheimer's Disease

DrugLecanemab

Eisai Inc.

Phase 3

1,906

Günzburg, Mannheim, Berlin, Bielefeld, Erbach im Odenwald, München

2019-03-27

Active, closed

Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.

NCT03869892Metastatic Colorectal Cancer

DrugsTrifluridine/Tipiracil·Capecitabine

Institut de Recherches Internationales Servier

Phase 3

856

Berlin, Lübeck, München

2019-03-21

Recruiting

Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)

NCT03981575Myotonic Dystrophy 1, DM1

Virginia Commonwealth University

Observational

700

München

2019-01-01

Active, closed

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

NCT03765918Head and Neck Neoplasms

DrugsKeytruda·Cisplatin·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

714

Tübingen, Ulm, Erlangen, Munich, München, Frankfurt am Main, Kassel, Cologne

2018-12-17

Recruiting

De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head-neck Squamous Cell Carcinomas

NCT03396718Head-and-neck Squamous Cell Carcinoma

Technische Universität Dresden

Not applicable

304

Tübingen, Essen, Dresden, Berlin, Frankfurt am Main, Freiburg im Breisgau, Heidelberg, München

2018-11-29

Active, closed

CoreHip - Post Market Clinical Follow-Up Study

NCT03685110Degenerative Osteoarthritis, Rheumatic Arthritis, Fractures, Hip, Necrosis, Femur Head

Aesculap AG

Observational

248

Markgröningen, München, Hanover, Salzkotten

2018-10-16

Recruiting

Extension Study for the Port Delivery System With Ranibizumab (Portal)

NCT03683251Neovascular Age-Related Macular Degeneration

DrugPDS Implant with Ranibizumab

Hoffmann-La Roche

Phase 3

1,000

Bonn, Cologne, Cottbus, Freiburg im Breisgau, Hamburg, Ludwigshafen, München, Münster

2018-09-20

Active, closed

Reducing Lung CongestIon Symptoms in Advanced Heart Failure

NCT03499236Heart Failure

V-Wave Ltd

Not applicable

605

Berlin, Hamburg, Leipzig, München, Remscheid, Rostock

2018-09-19

Active, closed

Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer

NCT03503799Primary Invasive Breast Cancer, Estrogen Receptor Positive Tumor, Human Epidermal Growth Factor Receptor 2 Negative Tumor

North Eastern German Society of Gynaecological Oncology

Observational

1,191

München, Berlin, Ansbach, Bremerhaven, Chemnitz, Dresden, Düsseldorf, Ebersberg

2018-07-17

Active, closed

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

NCT03625037DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL

DrugEpcoritamab

Genmab

Phase 1/2

666

Berlin, Cologne, Essen, Mainz, München

2018-06-26

Active, closed

A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.

NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsZolbetuximab·Folinic acid·Fluorouracil·Oxaliplatin

Astellas Pharma Global Development, Inc.

Phase 3

565

Munich, München, Mainz, Dresden, Leipzig, Halle, Magdeburg, Berlin

2018-06-21

Recruiting

Mucous Fistula Refeeding Reduces the Time From Enterostomy Closure to Full Enteral Feeds ("MUC-FIRE" Trial)

NCT03469609Enterostomy

University of Leipzig

Not applicable

120

Tübingen, München, Frankfurt am Main, Hanover, Witten, Mainz, Dresden, Leipzig

2018-06-18

Active, closed

Clinical and Radiological Outcomes of Medacta Shoulder System

NCT03547947Primary Osteoarthritis, Secondary Osteoarthritis, Rotator Cuff Tear Arthropathy, Rheumatoid Arthritis Shoulder

Medacta International SA

Observational

200

München

2018-06-13

Active, closed

AHEAD: European Feasibility Study of the Cardiovalve Transfemoral Mitral Valve System

NCT03339115Mitral Regurgitation, Mitral Valve Disease

Cardiovalve Ltd.

Not applicable

Bonn, Cologne, Lübeck, Mainz, München

2018-04-23

Active, closed

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

NCT03330847Metastatic Triple Negative Breast Cancer

DrugCeralasertib

AstraZeneca

Phase 2

273

Dresden, Frankfurt am Main, Hamburg, Hanover, Leipzig, München, Witten

2018-03-07

Active, closed

Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD

NCT03458832Facioscapulohumeral Muscular Dystrophy

University of Kansas Medical Center

Observational

324

München

2018-03-05

Active, closed

AMPLATZER PFO Occluder Post Approval Study

NCT03309332Stroke, Patent Foramen Ovale

Abbott Medical Devices

Not applicable

1,214

München, Berlin

2018-01-31

Active, closed

Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal Carcinoma

NCT02984410Oropharyngeal Cancer, Supraglottic Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma

European Organisation for Research and Treatment of Cancer - EORTC

Not applicable

112

Cologne, Halle, Hamburg, Jena, Leipzig, München, Tübingen, Ulm

2017-11-27

Active, closed

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

NCT03299049HIV Infections

DrugsRilpivirine·Cabotegravir

ViiV Healthcare

Phase 3

1,049

Berlin, Bonn, Essen, Frankfurt, Hamburg, Hanover, München

2017-10-27

Recruiting

Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study

NCT03373968Duchenne Muscular Dystrophy

DrugHydroxyurea

Italfarmaco

Phase 2/3

206

Essen, Hamburg, München

2017-10-24

Active, closed

Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

NCT03298451Hepatocellular Carcinoma

DrugsSorafenib·Tremelimumab·Durvalumab

AstraZeneca

Phase 3

1,324

Aachen, Cologne, Essen, Hanover, Heidelberg, Leipzig, Mainz, München

2017-10-11

Active, closed

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

NCT03148418Cancer

DrugsAvastin·Tecentriq·Atezolizumab·Bevacizumab

Hoffmann-La Roche

Phase 3

382

München

2017-09-20

Active, closed

A Study of AT132 in Young Children With X-Linked Myotubular Myopathy (XLMTM)

NCT03199469X-Linked Myotubular Myopathy

Astellas Gene Therapies

Phase 2/3

München

2017-08-02

Active, closed

A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease

NCT03100149Parkinson's Disease

DrugPrasinezumab

Hoffmann-La Roche

Phase 2

316

Berlin, Düsseldorf, Kassel, Leipzig, Marburg, München, Tübingen, Ulm

2017-06-27

Active, closed

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.

NCT03161353Breast Cancer

DrugsPerjeta·Herceptin·Tamoxifen·Pertuzumab

MedSIR

Phase 2

377

Essen, Halle, Heidelberg, Leipzig, Munich, München

2017-06-26

Active, closed

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation

NCT03173248Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute

DrugsIvosidenib·Azacitidine

Institut de Recherches Internationales Servier

Phase 3

146

Essen, Chemnitz, Berlin, Hanover, Leipzig, München, Ulm

2017-06-26

Recruiting

MED-EL HEARING SOLUTIONS (MEHS): AN OBSERVATIONAL STUDY

NCT05668338Hearing Loss

MED-EL Elektromedizinische Geräte GesmbH

Observational

100

Bochum, Dresden, Frankfurt, Heidelberg, München, Oldenburg, Rostock, Tübingen

2017-06-26

Active, closed

Non-interventional Study With NOVOCART® 3D for the Treatment of Cartilage Defects of the Knee in Pediatric Patients

NCT04186208Cartilage Disease

DrugNOVOCART 3D

Tetec AG

Observational

Mannheim, Stuttgart, München, Regensburg, Kiel

2017-04-25

Active, closed

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

NCT02972840Lymphoma, Mantle Cell

DrugsAcalabrutinib·Bendamustine·Rituximab

Acerta Pharma BV

Phase 3

635

Heidelberg, München, Münster, Nordrhein-Westfalen, Ravensburg, Rheinland-Pfalz, Ulm

2017-04-05

Active, closed

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

NCT02970318Chronic Lymphocytic Leukemia

DrugsIdelalisib·Acalabrutinib·Bendamustine·Rituximab

Acerta Pharma BV

Phase 3

310

Aschaffenburg, Dresden, Mutlangen, München, Ulm

2017-02-02

Recruiting

CArdioSurgEry Atrial Fibrillation Register

NCT03091452Atrial Fibrillation

Stiftung Institut fuer Herzinfarktforschung

Observational

2,000

München, Hamburg, Bad Rothenfelde

2017-01

Active, closed

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

NCT02951052Infection, Human Immunodeficiency Virus, HIV Infections

Drugs2 NRTIs·Cabotegravir (CAB)·Rilpivirine (RPV)·Rilpivirine

ViiV Healthcare

Phase 3

618

Berlin, Bonn, Essen, Frankfurt, Hamburg, Hanover, München

2016-10-28

Active, closed

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

NCT02938520HIV Infections

DrugsCabotegravir (CAB)·Rilpivirine (RPV)·Rilpivirine·Cabotegravir

ViiV Healthcare

Phase 3

631

Berlin, Bonn, Essen, Frankfurt, Hamburg, Hanover, München

2016-10-27

Active, closed

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

NCT02811861Renal Cell Carcinoma

DrugsSunitinib·Everolimus·Lenvatinib·Pembrolizumab

Eisai Inc.

Phase 3

1,069

Stuttgart, Tübingen, München, Frankfurt am Main, Hanover, Greifswald, Münster, Homburg/Saar

2016-10-13

Active, closed

2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients

NCT02917720Chronic Myeloid Leukemia

DrugNilotinib

European LeukemiaNet

Phase 2

Freiburg im Breisgau, Mannheim, München, Hannover, Aachen, Bayreuth, Chemnitz, Esslingen am Neckar

2016-09

Active, closed

Trial on Radical Upfront Surgery in Advanced Ovarian Cancer

NCT02828618Ovarian Cancer

AGO Study Group

Not applicable

797

Berlin, Dresden, Düsseldorf, Essen, Hamburg, München, Tübingen

2016-07

Active, closed

STAR-LIFE Registry: STARflo Glaucoma Implant Clinical Experience Program

NCT02825264Open Angle Glaucoma

iSTAR Medical

Observational

Dortmund, Heidelberg, München, Rostock

2016-07

Recruiting

The Transplant Cohort of the German Center for Infection Research

NCT06346665Infections, Transplant Complication, Transplant Failure, Immunosuppression

Technical University of Munich

Observational

3,000

München

2016-01

Active, closed

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

NCT02516241Urothelial Cancer

DrugsTremelimumab·Durvalumab·Gemcitabine·Cisplatin

AstraZeneca

Phase 3

1,126

Düsseldorf, Erlangen, Hanover, Heidelberg, Jena, München, Münster

2015-11-02

Active, closed

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

NCT02612454Atopic Dermatitis

DrugDupilumab

Regeneron Pharmaceuticals

Phase 3

880

Tübingen, Frankfurt am Main, Münster, Dresden, Gera, Hamburg, Munich, München

2015-10-15

Active, closed

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

NCT02477696Chronic Lymphocytic Leukemia

DrugsIbrutinib·Acalabrutinib

Acerta Pharma BV

Phase 3

533

München, Ulm

2015-07-28

Recruiting

Total Shoulder Arthroplasty Multi-Center Registry

NCT03511586Shoulder Arthroplasty

Arthrex, Inc.

Observational

2,500

München

2015-07-28

Recruiting

Valvular Heart Disease Registry

NCT03488732Valvular Heart Disease

Technical University of Munich

Observational

2,000

München

2015-04-01

Recruiting

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

NCT02332668Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma

DrugPembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

370

München

2015-03-19

Active, closed

Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

NCT02362503HIV Infections

ViiV Healthcare

Phase 3

371

Berlin, Dortmund, Frankfurt, Freiburg im Breisgau, München

2015-02-23

Active, closed

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

NCT02246621Breast Cancer

DrugsAnastrozole·Abemaciclib·Letrozole

Eli Lilly and Company

Phase 3

493

Ludwigsburg, Ulm, München, Wiesbaden, Düsseldorf, Lübeck, Hamburg

2014-11-06

Active, closed

A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer

NCT02107703Breast Neoplasms

DrugsAbemaciclib·Fulvestrant

Eli Lilly and Company

Phase 3

669

Ludwigsburg, Tübingen, Augsburg, München, Hamburg

2014-07-22

Recruiting

AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.

NCT02102165Metastatic Breast Cancer

Jules Bordet Institute

Not applicable

1,000

Essen, München

2014-04

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/m-nchen

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

Clinical Trials in München, 2026

Trials with a site in München

About this register

How many clinical trials are recruiting in München?

Summary by phase

Most active sponsors

Phase	Studies	Recruiting	Share
Phase 3	192	86	37.7%
Phase 2	93	42	18.3%
Observational	80	54	15.7%
Not applicable	68	43	13.4%
Phase 1/2	28	21	5.5%
Phase 1	25	17	4.9%
Phase 2/3	16	8	3.1%
Phase 4	7	5	1.4%